prednisone and Ache studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
"Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis."	9.27	The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. ( Brookman-May, SD; Carles, J; Diels, J; Gschwend, JE; Miller, K; Van Poppel, H, 2018)
"To assess the efficacy and safety of low-dose prednisone chronotherapy using a new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA)."	9.17	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). ( Alten, RE; Boers, M; Buttgereit, F; Kirwan, J; Mehta, D; Romer, U; Saag, KG; Supronik, J; Szechinski, J; Szombati, I; Witte, S, 2013)
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)."	9.14	Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010)
"Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)."	9.12	Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006)
"To determine if short-acting oral therapy with prednisone was more effective than placebo in alleviating the suffering from acute pharyngitis in adults in a general practice setting."	9.11	Adjuvant prednisone therapy in pharyngitis: a randomised controlled trial from general practice. ( Bregman, J; Furst, AL; Kiderman, A; Yaphe, J; Zemel, T, 2005)
"Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid."	9.10	Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003)
"In relatively healthy persons older than 50 years of age who have localized herpes zoster, combined acyclovir and prednisone therapy can improve quality of life."	9.08	Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. ( Gnann, JW; Hayden, F; Mertz, GJ; Pappas, PG; Schleupner, CJ; Soong, SJ; Tyring, S; Weiss, H; Whitley, RJ; Wolf, J, 1996)
"In a Nordic multi-centre trial, 583 previously untreated multiple myeloma patients were randomized to receive melphalan-prednisone or melphalan-prednisone+ interferon alpha-2b at a dose of 5 million units subcutaneously, 3 d/week."	9.08	Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. ( Hjorth, M; Kaasa, S; Westin, J; Wisløff, F, 1996)
"To determine the long-term efficacy and safety of low-dose methotrexate (MTX) in rheumatoid arthritis (RA)."	9.07	Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. ( Coblyn, JS; Falchuk, KR; Fraser, PA; Holdsworth, DE; Maier, AL; Weinblatt, ME; Weissman, BN, 1992)
"Prednisone, 5 mg taken each morning, was added to other drugs in 18 patients with rheumatoid arthritis."	9.05	Low dose prednisone therapy in rheumatoid arthritis: a double blind study. ( Emkey, RD; Harris, ED; Newberg, A; Nichols, JE, 1983)
"Patients treated with paclitaxel in the gynecologic oncology program of the Cleveland Clinic Foundation who developed arthralgias/myalgias which were uncontrolled through the use of nonsteroidal anti-inflammatory medications received low-dose oral prednisone (10 mg B."	7.70	Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1999)
"The eosinophilia-myalgia syndrome associated with the use of oral preparations of the amino acid L-tryptophan was recognized in late 1989."	7.68	Eosinophilia-myalgia syndrome associated with L-tryptophan use. ( Gertner, E; Glickstein, SL; Hathaway, DE; Roelofs, RI; Schlesinger, PA; Schned, ES; Smith, SA, 1990)
"We describe the spectrum of clinical and histologic abnormalities of 11 women with L-tryptophan induced eosinophilia-myalgia syndrome."	7.68	L-tryptophan induced eosinophilia-myalgia syndrome. ( Albanese, JM; Chartash, EK; Coffey, EL; Farmer, PM; Furie, RA; Given, WP; Kaplan, MH; Susin, M; Vishnubhakat, SM, 1990)
"We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)."	7.67	Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989)
"33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)."	7.67	M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988)
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7."	7.67	Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989)
"Abiraterone plus prednisone delays patient-reported pain progression and HRQoL deterioration in chemotherapy-naive patients with metastatic castration-resistant prostate cancer."	6.27	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. ( Autio, K; Basch, E; Cleeland, C; Fizazi, K; Griffin, T; Hao, Y; Kheoh, T; Li, S; Logothetis, CJ; Mainwaring, PN; Meyers, ML; Molina, A; Mulders, P; Rathkopf, D; Ryan, CJ; Shore, N; Smith, MR, 2013)
"In these prespecified exploratory analyses, there was no significant difference in pain or HRQOL when olaparib was added to abiraterone."	5.51	Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. ( Alekseev, B; Burgents, J; Chiuri, VE; Clarke, NW; Degboe, A; Fléchon, A; Gresty, C; Jassem, J; Jones, R; Kang, J; Kocak, I; Redfern, C; Saad, F; Sala, N; Thiery-Vuillemin, A; Wiechno, P, 2022)
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics."	5.29	Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996)
"Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis."	5.27	The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. ( Brookman-May, SD; Carles, J; Diels, J; Gschwend, JE; Miller, K; Van Poppel, H, 2018)
"Our study confirmed that pamidronate, prednisone, and guideline-recommended anticonvulsants were effective for reducing pain intensity for CPSP."	5.22	Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. ( Bo, Z; Gangfeng, G; Jian, W; Jian, Y; Ke, H; Maoxia, L; Xiaojing, L; Xiaolan, L; Yan, L; Yang, F; Zhao, C, 2022)
"To assess the efficacy and safety of low-dose prednisone chronotherapy using a new modified-release (MR) formulation for the treatment of rheumatoid arthritis (RA)."	5.17	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). ( Alten, RE; Boers, M; Buttgereit, F; Kirwan, J; Mehta, D; Romer, U; Saag, KG; Supronik, J; Szechinski, J; Szombati, I; Witte, S, 2013)
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)."	5.14	Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010)
"To investigate the use of docetaxel 75 mg/m(2) intravenously every 3 weeks plus prednisone 5 mg orally twice daily in men with metastatic hormone-refractory prostate cancer (HRPC) progressing after first-line mitoxantrone/prednisone (MP), the primary outcome being progression-free survival with prostatic-specific antigen (PSA) and pain response, toxicity and quality of life (QoL) also assessed."	5.13	The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. ( Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E, 2008)
"Palliation of bone pain can be achieved in men with androgen-independent prostate cancer treated with docetaxel and estramustine (DE) or mitoxantrone and prednisone (MP)."	5.12	Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. ( Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV, 2006)
"This study clearly showed the efficacy of a short course of oral prednisone (3 days), versus a placebo, in the treatment of the functional signs of acute maxillary rhinosinusitis with severe pain in adults in addition to an appropriate antibiotic treatment."	5.11	[Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days]. ( Bordure, P; Coriat, F; Deslandes, B; Desmonts-Gohler, C; Dubreuil, C; Gehanno, P; Gilain, L; Jankowski, R; Klossek, JM; Serrano, E; Stoll, D, 2004)
" Adult patients (>21 years old) with early RA (symptom duration <1 year) and severe joint pain under maximal dose of nonsteroidal anti-inflammatory drugs (NSAIDS) were started on low-dose prednisone (10 mg/day)."	5.11	Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. ( Habib, GS; Haj, S, 2005)
"To determine if short-acting oral therapy with prednisone was more effective than placebo in alleviating the suffering from acute pharyngitis in adults in a general practice setting."	5.11	Adjuvant prednisone therapy in pharyngitis: a randomised controlled trial from general practice. ( Bregman, J; Furst, AL; Kiderman, A; Yaphe, J; Zemel, T, 2005)
"Men with HRPC, bone metastases, and bone pain were randomly assigned to receive clodronate 1,500 mg administered intravenously (IV) or placebo every 3 weeks, in combination with mitoxantrone 12 mg/m2 IV every 3 weeks and prednisone 5 mg orally bid."	5.10	Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. ( Chi, K; Ding, K; Elliott, C; Ernst, DS; Moore, MJ; Parulekar, W; Reyno, L; Tannock, IF; Venner, PM; Winquist, EW, 2003)
"In relatively healthy persons older than 50 years of age who have localized herpes zoster, combined acyclovir and prednisone therapy can improve quality of life."	5.08	Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. ( Gnann, JW; Hayden, F; Mertz, GJ; Pappas, PG; Schleupner, CJ; Soong, SJ; Tyring, S; Weiss, H; Whitley, RJ; Wolf, J, 1996)
"Measurement of health-related quality of life was integrated into a randomized trial (NMSG 4/90) comparing melphalan/prednisone to melphalan/prednisone + interferon alpha-2b in newly diagnosed multiple myeloma."	5.08	Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. ( Hjorth, M; Wisløff, F, 1997)
"In a Nordic multi-centre trial, 583 previously untreated multiple myeloma patients were randomized to receive melphalan-prednisone or melphalan-prednisone+ interferon alpha-2b at a dose of 5 million units subcutaneously, 3 d/week."	5.08	Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. ( Hjorth, M; Kaasa, S; Westin, J; Wisløff, F, 1996)
"We randomized 161 hormone-refractory patients with pain to receive mitoxantrone plus prednisone or prednisone alone (10 mg daily)."	5.08	Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. ( Armitage, GR; Coppin, CM; Ernst, DS; Moore, MJ; Murphy, KC; Neville, AJ; Osoba, D; Stockler, MR; Tannock, IF; Venner, PM; Wilson, JJ, 1996)
"To determine the long-term efficacy and safety of low-dose methotrexate (MTX) in rheumatoid arthritis (RA)."	5.07	Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. ( Coblyn, JS; Falchuk, KR; Fraser, PA; Holdsworth, DE; Maier, AL; Weinblatt, ME; Weissman, BN, 1992)
"Prednisone, 5 mg taken each morning, was added to other drugs in 18 patients with rheumatoid arthritis."	5.05	Low dose prednisone therapy in rheumatoid arthritis: a double blind study. ( Emkey, RD; Harris, ED; Newberg, A; Nichols, JE, 1983)
"A 14-day, single-blind trial of prednisone, aspirin, and placebo was carried out in 128 patients suffering from rheumatoid arthritis, using subjective criteria only (severity of pain daily on a pain chart and assessment of the drug for effectiveness)."	5.04	Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. ( Anderson, J; Buchanan, WW; Lee, P; Webb, J, 1973)
" As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated."	4.81	Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001)
" The evaluated palliative treatments were pain medication only, chemotherapy consisting of mitoxantrone and prednisone, and single- and multifraction radiotherapy (RT)."	3.72	Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. ( Konski, A, 2004)
"Patients treated with paclitaxel in the gynecologic oncology program of the Cleveland Clinic Foundation who developed arthralgias/myalgias which were uncontrolled through the use of nonsteroidal anti-inflammatory medications received low-dose oral prednisone (10 mg B."	3.70	Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. ( Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K, 1999)
"We describe the spectrum of clinical and histologic abnormalities of 11 women with L-tryptophan induced eosinophilia-myalgia syndrome."	3.68	L-tryptophan induced eosinophilia-myalgia syndrome. ( Albanese, JM; Chartash, EK; Coffey, EL; Farmer, PM; Furie, RA; Given, WP; Kaplan, MH; Susin, M; Vishnubhakat, SM, 1990)
"The eosinophilia-myalgia syndrome associated with the use of oral preparations of the amino acid L-tryptophan was recognized in late 1989."	3.68	Eosinophilia-myalgia syndrome associated with L-tryptophan use. ( Gertner, E; Glickstein, SL; Hathaway, DE; Roelofs, RI; Schlesinger, PA; Schned, ES; Smith, SA, 1990)
"We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)."	3.67	Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989)
"Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7."	3.67	Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989)
"33 patients with advanced refractory multiple myeloma received a combination of vincristine, cyclophosphamide, carmustine, melphalan and steroids (M-2 protocol)."	3.67	M-2 protocol for melphalan-resistant and relapsing multiple myeloma. ( Cavo, M; Galieni, P; Gobbi, M; Tassi, C; Tura, S, 1988)
"Facial swelling, pain, and trismus are the most common postoperative sequelae after mandibular third molar (M3M) surgery."	3.30	Three-dimensional facial swelling evaluation of pre-operative single-dose of prednisone in third molar surgery: a split-mouth randomized controlled trial. ( Antonelli, A; Barone, S; Bennardo, F; Giudice, A, 2023)
"The average treatment levels of pain did not differ, hence, the average mediated effect of treatment on GHRQL was zero."	2.74	Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. ( Donaldson, GW; Moinpour, CM; Nakamura, Y, 2009)
"Acute neuritis and persistent pain are the most significant clinical manifestations of herpes zoster and are end points for clinical trials therapy."	2.69	Herpes zoster: risk categories for persistent pain. ( Gnann, JW; Soong, SJ; Weiss, HL; Whitley, RJ, 1999)
"The prednisone therapy was differentiated by improvement from that of a placebo by six of the nine parameters evaluated."	2.67	Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. ( Fiechtner, JJ; Johnson, LK; Miller, DR; Rice, JR; Stenberg, VI, 1992)
"Pain is historically considered a cardinal sign of acute inflammation and a predominant symptom of IOIS."	2.46	Idiopathic orbital inflammatory syndrome without pain: a case report. ( Boothe, KH; Eckermann, DR; Musick, AN; Slagle, AM; Slagle, WS, 2010)
"Fever, arthritis and skin rash was constant."	2.41	[Adult Still's disease: study of a series of 11 cases]. ( Ben Maïz, H; Ben Taarit, C; Turki, S, 2002)
"Persistent pain is the most debilitating sequela and it occurs in at least 15% of individuals over 50 years of age."	2.40	Therapeutic approaches to the management of herpes zoster. ( Gnann, JW; Whitley, RJ, 1999)
"The neurologic manifestations of coronavirus disease 2019 (COVID-19) are wide-ranging, including various cranial neuropathies, beyond anosmia and dysgeusia, the exact neuropathological mechanism of which are yet unknown."	1.62	Stridor Due to Cranial Nerve X Palsy Progressing to Polyneuropathy in a Teenager With COVID-19. ( Chelius, D; Dean, A; Marri, K; Said, A, 2021)
"A 50% improvement of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or a final BASDAI score of <4 according to disease activity at baseline was chosen as the primary outcome parameter after MR prednisone."	1.43	Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. ( Bandinelli, F; Barreto Santiago, M; Marcassa, C; Matucci Cerinic, M; Nacci, F; Pimenta da Fonseca, E; Scazzariello, F, 2016)
"A treatment with prednisone was introduced, and the patient's condition significantly improved."	1.42	[Neuralgic amyotrophy--a case report]. ( Banach, M; Miller, M, 2015)
"Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils."	1.34	Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007)
"Pain is a common problem in both adults and children with Guillain-Barré Syndrome (GBS)."	1.32	[Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome]. ( Boukhris, S; Kabore, R; Lacoste, M; Mabrouk, T; Magy, L; Vallat, JM, 2004)
"Orbital emphysema is a common complication of orbital wall fractures (50% of blow-out fractures)."	1.32	[Emergency treatment of post-traumatic orbital emphysema: a case report]. ( Benharbit, M; Karim, A; Lazreq, M; Mohcine, Z, 2003)
"Subacute thyroiditis (SAT), or granulomatous thyroiditis, is an inflammatory thyroid condition associated with pain and systemic symptoms."	1.32	Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. ( Aniszewski, JP; Atkinson, EJ; Fatourechi, GZ; Fatourechi, V; Jacobsen, SJ, 2003)
"Patients with chronic immune thrombocytopenic purpura (ITP) who are unresponsive to corticosteroids require splenectomy, but if this fails, treatment is difficult."	1.31	Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. ( Kappers-Klunne, MC; van't Veer, MB, 2001)
"Lymphadenitis at the right side of his neck preceded the symptoms."	1.30	Painful Horner syndrome due to arteritis of the internal carotid artery. ( Bollen, AE; de Jager, AE; Krikke, AP, 1998)
"Three patients with Sjogren's syndrome are presented in whom frequent tonic/dystonic spasms of the limbs developed during the course of the illness."	1.30	Painful tonic/dystonic spasms in Sjogren's syndrome. ( Jabbari, B; Salardini, A, 1999)
"When pain was asymmetric, the SSR amplitude was higher in the arm with greater pain."	1.29	The sympathetic skin response in the shoulder-hand syndrome complicating tetraplegia. ( Aisen, ML; Aisen, PS; Stallman, J, 1995)
"In type I Gaucher's disease, episodes of severe disabling bone pain, the so called bone crises, may be resistant to all analgesics, including narcotics."	1.29	Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. ( Cohen, IJ; Katz, K; Kornreich, L; Mekhmandarov, S; Zaizov, R, 1996)
"Two boys with acute lymphocytic leukemia (ALL) who presented with muscle pain, shortly after receiving induction chemotherapy, were evaluated."	1.29	Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. ( Corden, TE; Morgan, ER, 1996)
"Pain is not usually considered a symptom of chronic relapsing demyelinating polyneuropathy."	1.29	Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates. ( Brunet, DG; Zochodne, DW, 1994)
"Findings at necropsy included necrotizing arteritis with fibrinoid necrosis, periarteritis, thrombosis, and intimal proliferation that most frequently affected small- to medium-sized vessels in the cervical spinal cord, mediastinum, and heart."	1.28	Systemic necrotizing vasculitis in nine young beagles. ( Davis, EL; Felsburg, PJ; Glickman, LT; Scott-Moncrieff, JC; Snyder, PW, 1992)
"A patient with primary Hodgkin's disease of the lung is described."	1.27	Primary Hodgkin's disease of the lung. Case report and review of the literature. ( Czembirek, H; Homan, R; Lechner, K; Moritz, H; Neumann, E; Resch, F, 1983)
"The pains were resistant to various analgesics."	1.27	Bone lesions in hairy cell leukemia. A case report and response of bone pains to steroids. ( Arkel, YS; Berman, E; Lake-Lewin, D; Savopoulos, AA, 1984)
"Progressive diaphyseal dysplasia is characterized clinically by crippling leg pain, fatigue, headache, poor appetite, muscle weakness, and waddling gait."	1.27	Progressive diaphyseal dysplasia: evaluation of corticosteroid therapy. ( Alon, U; Berant, M; Kaftori, JK; Naveh, Y, 1985)
"Aseptic necrosis of the wrist in systemic lupus erythematosus (SLE) is not rare."	1.26	Aseptic necrosis presenting as wrist pain in SLE. ( Abeles, M; Houghton, AN; Rothfield, NF; Urman, JD, 1977)
"Prednisone therapy was associated with complete clearing of all clinical and laboratory abnormalities."	1.26	Hepatitis-associated lipid storage myopathy. ( Alperin, J; Dodson, RF; Patten, BM; Shabot, JM, 1977)
"Pain and ophthalmoplegia were both relatively late manifestations preceded for several weeks by progressive involvement of the optic nerve."	1.26	Unusual course of painful ophthalmoplegia. Report of a case. ( Andersson, BI, 1980)
"Criteria for the diagnosis of multiple myeloma and differential diagnostic considerations are presented."	1.26	[Prognosis and therapy of multiple myeloma]. ( Sonntag, RW, 1978)
"A review of 869 cases of multiple myeloma seen at the Mayo Clinic from 1960 through 1971 revealed that 98% of patients were 40 years of age or older and that 61% of them were males."	1.25	Multiple myeloma: review of 869 cases. ( Kyle, RA, 1975)
" Dose-response studies indicate that bradykinin is more potent than serotonin or histamine in respect of wealing."	1.25	Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. ( Greaves, M; Shuster, S, 1967)
"Carotid system arteritis may be easily overlooked in everyday practice."	1.25	Carotid system arteritis: an overlooked and misdiagnosed syndrome. ( Gaston, GW; Troiano, MF, 1975)

Research

Studies (212)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

Timeframe	Studies, this research(%)	All Research%
pre-1990	86 (40.57)	18.7374
1990's	36 (16.98)	18.2507
2000's	47 (22.17)	29.6817
2010's	31 (14.62)	24.3611
2020's	12 (5.66)	2.80

Authors	Studies
Zareie, F	1
Ghalebandi, S	1
Askari, K	1
Mousavi, Z	1
Haghparast, A	1
Dean, A	1
Said, A	1
Marri, K	1
Chelius, D	1
Procopio, G	1
Chiuri, VE	2
Giordano, M	1
Alitto, AR	1
Maisano, R	1
Bordonaro, R	1
Cinieri, S	1
Rossetti, S	1
De Placido, S	1
Airoldi, M	1
Galli, L	1
Gasparro, D	1
Ludovico, GM	1
Guglielmini, PF	1
Carella, C	1
Nova, P	1
Aglietta, M	1
Schips, L	1
Beccaglia, P	1
Sciarra, A	1
Livi, L	1
Santini, D	1
Bo, Z	1
Jian, Y	1
Yan, L	1
Gangfeng, G	1
Xiaojing, L	1
Xiaolan, L	1
Zhao, C	1
Ke, H	1
Yang, F	1
Maoxia, L	1
Jian, W	1
Saad, F	2
Thiery-Vuillemin, A	1
Wiechno, P	1
Alekseev, B	1
Sala, N	1
Jones, R	1
Kocak, I	1
Jassem, J	1
Fléchon, A	1
Redfern, C	1
Kang, J	1
Burgents, J	1
Gresty, C	1
Degboe, A	1
Clarke, NW	1
Oyenuga, M	1
Halabi, S	2
Oyenuga, A	1
McSweeney, S	1
Morgans, AK	1
Ryan, CJ	2
Prizment, A	1
Kurup, V	1
Nagoshi, Y	1
Rivera-Zengotita, M	1
Maska, E	1
Antonelli, A	1
Barone, S	1
Bennardo, F	1
Giudice, A	1
Tidwell, C	1
Willman, A	1
Mir, TH	1
Sharma, A	1
Nisar, S	1
Khan, AA	1
Shah, TA	1
Wani, NA	1
Nozawa, T	1
Bell-Peter, A	1
Doria, AS	1
Marcuz, JA	1
Stimec, J	1
Whitney, K	1
Feldman, BM	1
Trejo, F	1
Garrell, X	1
Banderas, S	1
Aragón, D	1
Iribarren, MDC	1
Segura, A	1
Miller, K	1
Carles, J	1
Gschwend, JE	1
Van Poppel, H	1
Diels, J	1
Brookman-May, SD	1
Bhatia, S	1
Herrera Hernandez, LP	1
Kamboj, AK	1
Rieck, KM	1
Culine, S	1
Kelly, NP	1
Vaidya, A	1
Gerhard-Herman, M	1
Desai, AS	1
Lieba-Samal, D	1
van Eijk, JJJ	1
van Rosmalen, MHJ	1
van Balken, IMF	1
Verrips, A	1
Mostert, J	1
Pillen, S	1
van Alfen, N	2
Allison, C	1
DeBiegun, G	1
Hannah, CE	1
Moye, MS	1
Wanat, KA	1
Liu, V	1
Efe, C	1
Ozaslan, E	1
Purnak, T	1
Puente, J	1
González-Del-Alba, A	1
Sala-Gonzalez, N	1
Méndez-Vidal, MJ	1
Pinto, A	1
Rodríguez, Á	1
Cuevas Sanz, JM	1
Muñoz Del Toro, JR	1
Useros Rodríguez, E	1
García García-Porrero, Á	1
Vázquez, S	1
Antaki, N	1
Abboud, D	1
Basch, E	1
Autio, K	1
Mulders, P	1
Shore, N	1
Kheoh, T	1
Fizazi, K	1
Logothetis, CJ	1
Rathkopf, D	1
Smith, MR	1
Mainwaring, PN	1
Hao, Y	1
Griffin, T	1
Li, S	1
Meyers, ML	1
Molina, A	1
Cleeland, C	1
Lin, CY	1
Small, EJ	1
Armstrong, AJ	2
Kaplan, EB	1
Petrylak, D	1
Sternberg, CN	1
Shen, L	1
Oudard, S	1
de Bono, J	1
Sartor, O	1
Mosholt, KS	1
Dahl, C	1
Azawi, NH	1
Kararizou, E	1
Anagnostou, E	1
Kapaki, E	1
Davaki, P	1
Shah, KK	1
Tarasova, V	1
Davidian, M	1
Anderson, RJ	1
Benucci, M	1
Olivito, B	1
Manfredi, M	1
Meacci, F	1
Infantino, M	1
Li Gobbi, F	1
Sarzi-Puttini, P	1
Marcassa, C	2
Atzeni, F	1
Buttgereit, F	2
Kent, JD	1
Holt, RJ	1
Grahn, AY	1
Rice, P	1
Alten, R	1
Yazici, Y	1
Maroz, N	1
Field, H	1
Miller, M	1
Banach, M	1
Iudici, M	1
Vettori, S	1
Russo, B	1
Giacco, V	1
Capocotta, D	1
Valentini, G	1
Bandinelli, F	1
Scazzariello, F	1
Pimenta da Fonseca, E	1
Barreto Santiago, M	1
Nacci, F	1
Matucci Cerinic, M	1
Ruether, D	1
Ernst, S	1
North, S	1
Cheng, T	1
Perrotte, P	1
Karakiewicz, P	1
Winquist, E	1
Moinpour, CM	2
Donaldson, GW	1
Nakamura, Y	1
Rogo, T	1
Kamat, R	1
Arabshahi, B	1
Lateef, T	1
Kuba, S	1
Yamaguchi, J	1
Ohtani, H	1
Shimokawa, I	1
Maeda, S	1
Kanematsu, T	1
Buch-Hansen, TZ	1
Bentzen, L	1
Hansen, S	1
Hoeyer, M	1
Jensen, NV	1
Saxe, C	1
Sengeloev, L	1
Ibrahimi, OA	1
Gunawardane, N	1
Sepehr, A	1
Reynolds, RV	1
Fournié, B	1
Zabraniecki, L	1
Lemaire, O	1
Plaut-Gaty, MA	1
Poix-Jover, E	1
Slagle, WS	1
Boothe, KH	1
Musick, AN	1
Eckermann, DR	1
Slagle, AM	1
Wolfe, KC	1
Poma, R	1
Wijermans, P	1
Schaafsma, M	1
Termorshuizen, F	1
Ammerlaan, R	1
Wittebol, S	1
Sinnige, H	1
Zweegman, S	1
van Marwijk Kooy, M	1
van der Griend, R	1
Lokhorst, H	1
Sonneveld, P	1
Hanspal, RS	1
Maynard, JW	1
Christopher-Stine, L	1
Gelber, AC	1
Browning, J	1
Russell, EL	1
Kellogg, N	1
Mehta, D	1
Kirwan, J	1
Szechinski, J	1
Boers, M	1
Alten, RE	1
Supronik, J	1
Szombati, I	1
Romer, U	1
Witte, S	1
Saag, KG	1
Meulenbeld, HJ	1
van Werkhoven, ED	1
Coenen, JL	1
Creemers, GJ	1
Loosveld, OJ	1
de Jong, PC	1
Ten Tije, AJ	1
Fosså, SD	1
Polee, M	1
Gerritsen, W	1
Dalesio, O	1
de Wit, R	3
Fatourechi, V	1
Aniszewski, JP	1
Fatourechi, GZ	1
Atkinson, EJ	1
Jacobsen, SJ	1
Kahlifa, M	1
Buckstein, R	1
Perez-Ordoñez, B	1
Meier, P	1
Gilabert, C	1
Burnier, M	1
Blanc, E	1
Ernst, DS	2
Tannock, IF	2
Winquist, EW	1
Venner, PM	2
Reyno, L	1
Moore, MJ	3
Chi, K	1
Ding, K	1
Elliott, C	1
Parulekar, W	1
Kawasaki, A	1
Borruat, FX	1
JACOBS, EM	1
ARCANGELI, P	1
CORRADI, F	1
D AYALAVALVA, G	1
GROSSMAN, H	1
BERDON, WE	1
BAKER, DH	1
CLOUSE, ME	1
HARTLEY, J	1
Grigg, A	1
Solal-Celigny, P	1
Hoskin, P	1
Taylor, K	1
McMillan, A	1
Forstpointner, R	1
Bacon, P	1
Renwick, J	1
Hiddemann, W	1
Benharbit, M	1
Karim, A	1
Lazreq, M	1
Mohcine, Z	1
Ferrari, TC	1
Moreira, PR	1
Cunha, AS	1
Klossek, JM	1
Desmonts-Gohler, C	1
Deslandes, B	1
Coriat, F	1
Bordure, P	1
Dubreuil, C	1
Gehanno, P	1
Gilain, L	1
Jankowski, R	1
Serrano, E	1
Stoll, D	1
Chun, CS	1
Webner, D	1
Drezner, JA	1
Foroozan, R	1
Ferrari, S	1
Lanzafame, M	1
Faggian, F	1
Malena, M	1
Cruciani, M	1
Cauallaro, T	1
Rizzutol, N	1
Concia, E	1
Vento, S	1
Río, J	1
Nos, C	1
Bonaventura, I	1
Arroyo, R	1
Genis, D	1
Sureda, B	1
Ara, JR	1
Brieva, L	1
Martín, J	1
Saiz, A	1
Sánchez López, F	1
Prieto, JM	1
Roquer, J	1
Dorado, JF	1
Montalban, X	1
Merli, F	1
Bertini, M	1
Luminari, S	1
Mozzana, R	1
Bertè, R	1
Trottini, M	1
Stelitano, C	1
Botto, B	1
Pizzuti, M	1
Quintana, G	1
De Paoli, A	1
Federico, M	1
Habib, GS	1
Haj, S	1
Kabore, R	1
Magy, L	1
Boukhris, S	1
Mabrouk, T	1
Lacoste, M	1
Vallat, JM	1
Konski, A	1
Kiderman, A	1
Yaphe, J	1
Bregman, J	1
Zemel, T	1
Furst, AL	1
Kaul, DR	1
Flanders, SA	1
Saint, S	1
Lin, PT	1
Andersson, PB	1
Distad, BJ	1
Barohn, RJ	1
Cho, SC	1
So, YT	1
Katz, JS	1
Reichenberg, JS	1
Sagar, S	1
Davis, MD	1
Ríos, G	1
van Engelen, BG	1
Berry, DL	1
Jiang, CS	1
Ankerst, DP	1
Petrylak, DP	1
Vinson, LV	1
Lara, PN	1
Jones, S	1
Taplin, ME	1
Burch, PA	1
Hussain, MH	1
Crawford, ED	1
Kozora, E	1
Ellison, MC	1
West, S	1
Weber, A	1
Mirzoyev, S	1
Anavekar, N	1
Zafeiriou, DI	1
Vargiami, E	1
Kröber, SM	1
Couillard, S	1
Benkerrou, M	1
Girot, R	1
Brousse, V	1
Ferster, A	1
Bader-Meunier, B	1
Grunwald, MH	1
Amichai, B	1
Ambrocio, DU	1
Uramoto, K	1
Garrett-Mayer, E	1
Ou Yang, YC	1
Carducci, MA	1
Tannock, I	2
Eisenberger, M	2
Berthold, DR	1
Pond, GR	1
Roessner, M	1
Tannock, AI	1
Greaves, M	1
Shuster, S	1
Other, A	1
Strum, WB	1
Beaver, WT	1
Arkel, YS	1
Lake-Lewin, D	1
Savopoulos, AA	1
Berman, E	1
Bradley, WG	1
Chad, D	1
Verghese, JP	1
Liu, HC	1
Good, P	1
Gabbai, AA	1
Adelman, LS	1
Harris, ED	1
Emkey, RD	1
Nichols, JE	1
Newberg, A	1
Engber, PB	1
Marino, CT	1
Portegies, P	1
Vanneste, JA	1
Larson, TS	1
Hall, S	1
Hepper, NG	1
Hunder, GG	1
Homan, R	1
Lechner, K	1
Neumann, E	1
Moritz, H	1
Czembirek, H	1
Resch, F	1
Goodman, BW	1
Shepard, FA	1
Andersson, BI	1
Hunt, GR	1
Giessel, M	1
Rau, JM	1
Sørensen, JB	1
Higuchi, I	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate [NCT01972217]	Phase 2	158 participants (Actual)	Interventional	2014-04-01	Completed
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer[NCT00887198]	Phase 3	1,088 participants (Actual)	Interventional	2009-04-28	Completed
Docetaxel and Estramustine Versus Mitoxantrone and Prednisone for Advanced, Hormone Refractory Prostate Cancer[NCT00004001]	Phase 3	770 participants (Actual)	Interventional	1999-10-31	Completed
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170]	Phase 2	50 participants (Anticipated)	Interventional	2018-12-31	Recruiting
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603]		100 participants (Anticipated)	Observational	2021-11-30	Recruiting
A Randomized Multi-Center, Double-Blind, Placebo-Controlled Study of a New Modified-Release Tablet Formulation of Prednisone (Lodotra®) in Patients With Rheumatoid Arthritis[NCT00650078]	Phase 3	350 participants (Actual)	Interventional	2008-03-31	Completed
Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis[NCT01837433]	Phase 4	40 participants (Actual)	Interventional	2013-03-31	Completed
Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232]	Phase 3	227 participants (Actual)	Interventional	1997-11-24	Completed
LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258]	Phase 4	50 participants (Anticipated)	Interventional	2006-10-31	Completed
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733]	Phase 4	50 participants (Anticipated)	Interventional	2017-09-25	Recruiting
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis[NCT01671423]		42 participants (Actual)	Interventional	2012-08-31	Completed
Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286]	Phase 2	140 participants (Anticipated)	Interventional	2017-11-30	Not yet recruiting
Phase II Multicenter Study Evaluating the Efficacy of Carboplatin-Etoposide Combination in Hormone-resistant Prostate Cancers With Neuroendocrine Differentiation.[NCT00973882]	Phase 2	60 participants (Actual)	Interventional	2005-04-30	Completed
A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone[NCT03261336]	Phase 2	1 participants (Actual)	Interventional	2017-01-06	Terminated (stopped due to can not meet enrollment)
Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17, Demonstration of Double-blind Trial Results[NCT03558971]	Phase 4	2,430 participants (Actual)	Interventional	2000-01-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

"DLTs were assessed by a Safety Review Committee (SRC) after a minimum of 3 patients had received at least 14 days of treatment in Part A.~A DLT was defined as any toxicity which was not a recognised AE of abiraterone or prednisolone, and was not attributable to the disease or disease-related processes under investigation, which occurred during a minimum period of 14 days treatment and which included: 1. haematological toxicity CTCAE v4.0 Grade 4 or higher present for more than 4 days (except anaemia); 2. non-haematological toxicity CTCAE v4.0 Grade 3 or higher including infection, corrected QT interval prolongation; 3. any other toxicity that was greater than that at baseline, was clinically significant and/or unacceptable, did not respond to supportive care, resulted in a disruption of dosing schedule of 7 days or more, or was judged to be a DLT by the SRC.~A DLT excluded alopecia and isolated laboratory changes of any grade without clinical sequelae or clinical significance." (NCT01972217)
Timeframe: From Day 1 for Cohort 1 and from Day 4 for Cohort 2 up to 14 days treatment with olaparib + abiraterone for 3 patients.

Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

Intervention	Patients (Number)
Part A Cohort 1: Olaparib 200 mg + Abiraterone	2
Part A Cohort 2: Olaparib 300 mg + Abiraterone	4

"The median best percentage change from baseline in CTC levels was determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest CTC level reduction compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

Intervention	Percentage change in CTC level (Median)
Part B: Olaparib + Abiraterone	-1.0
Part B: Placebo + Abiraterone	-1.0

"The best percentage change from baseline in PSA levels was determined to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~The best percentage change was defined as the biggest reduction in PSA level compared with baseline or smallest increase in the absence of a decrease." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

Part B: Median Overall Survival (OS)

Intervention	Percentage change in PSA level (Median)
Part B: Olaparib + Abiraterone	-54.16
Part B: Placebo + Abiraterone	-49.85

"OS was determined to assess the efficacy of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~OS was performed at the time of the analysis of rPFS, and the median OS, calculated using the Kaplan-Meier technique, is presented." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Part B: Median Radiological Progression-Free Survival (rPFS) Time

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	22.7
Part B: Placebo + Abiraterone	20.9

"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 (for soft tissue disease) and Prostate Cancer Working Group 2 (PCWG-2) (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit)." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Part B: Median Time to Second Progression or Death (PFS2)

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	13.8
Part B: Placebo + Abiraterone	8.2

The efficacy of olaparib when given in combination with abiraterone was assessed by PFS2, defined by local standard clinical practice and included objective radiological progression by RECIST 1.1 (soft tissue), symptomatic progression, rise in PSA level or death in the absence of overall progression. (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).

Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

Intervention	Months (Median)
Part B: Olaparib + Abiraterone	23.3
Part B: Placebo + Abiraterone	18.5

"The overall radiological ORR was calculated to assess the anti-tumour activity of olaparib in combination with abiraterone, compared with placebo in combination with abiraterone.~The best overall ORR was defined as the percentage of patients with at least 1 visit response of complete response (CR) or partial response (PR) in soft tissue disease assessed by RECIST 1.1 and also bone scan status of non-progressive disease or non-evaluable for their bone scans assessed by PCWG-2.~CR: Disappearance of all target lesions. Reduction of pathological lymph nodes to <10 millimetres.~PR: At least a 30% decrease in the sum of diameters of target lesions from baseline.~The percentage of patients with a response is presented." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 52, and then every 12 weeks.

Part B: Percentage of Patients With Progression Events or Death (rPFS)

Intervention	Percentage of patients (Number)
Part B: Olaparib + Abiraterone	27.3
Part B: Placebo + Abiraterone	31.6

"The efficacy of olaparib when given in combination with abiraterone was assessed by rPFS, defined as the time from randomisation to disease progression using RECIST version 1.1 (for soft tissue disease) and PCWG-2 (for bone disease) criteria, or death.~Progression using RECIST 1.1 criteria was defined as at least 20% increase from baseline in the sum of diameters of target lesions, progression of existing non-target lesions, or the appearance of at least 1 new lesion.~Progression using PCWG-2 criteria was determined if 2 or more new metastatic bone lesions were observed (with a total of at least 4 new lesions since baseline assessment if observed at the 12 week scan, or persistence of or increase in number of lesions if observed after the 12 week scan as determined by a confirmatory scan at least 6 weeks later or at next scheduled visit).~The percentage of patients with progression events is presented overall and according to RECIST 1.1 and/or PCWG-2 criteria, or death." (NCT01972217)
Timeframe: From baseline, every 12 weeks up to Week 72, then every 24 weeks up to 24 months.

Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

Intervention	Percentage of patients (Number)
Part B: Olaparib + Abiraterone	64.8
Part B: Placebo + Abiraterone	76.1

"The TFST and TSST were determined to assess the anti-tumour activity of olaparib when given in combination with abiraterone, compared with placebo given in addition to abiraterone.~TFST was defined as the time from randomisation to the earlier of first subsequent anti-cancer therapy start date following study treatment discontinuation, or death.~TSST was defined as the time from randomisation to the earlier of the second subsequent anti-cancer therapy start date following study treatment discontinuation, or death." (NCT01972217)
Timeframe: From randomisation until analysis cut-off date (up to approximately 3 years).

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Intervention	Months (Median)
	TFST	TSST
Part B: Olaparib + Abiraterone	13.5	19.6
Part B: Placebo + Abiraterone	9.7	18.0

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Intervention	micrograms per millilitre (mcg/mL) (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	7.724

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Intervention	micrograms per millilitre (mcg/mL) (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	7.781	6.504

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib AUCss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Intervention	mcg*h/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	49.51

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Intervention	mcg*h/mL (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	45.27	40.83

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib Cmin,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Intervention	mcg/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	1.279

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Intervention	mcg/mL (Geometric Mean)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	1.264	0.9170

"Following multiple dosing to steady state of olaparib 300 mg bid, the Cohort 2 olaparib tmax,ss is presented for olaparib monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Intervention	Hours (h) (Median)
	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	2.000

Part A PK: Abiraterone AUCss

Intervention	Hours (h) (Median)
	Olaparib alone	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	2.000	2.080

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone AUCss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone AUCss

Intervention	ng*h/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	718.9

Part A PK: Abiraterone Cmax,ss

Intervention	ng*h/mL (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	825.5	524.6

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Cmax,ss

Intervention	nanograms per millilitre (ng/mL) (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	130.7

Part A PK: Abiraterone Cmin,ss

Intervention	nanograms per millilitre (ng/mL) (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	145.8	86.12

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone Cmin,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Cmin,ss

Intervention	ng/mL (Geometric Mean)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	7.983

Part A PK: Abiraterone Tmax,ss

Intervention	ng/mL (Geometric Mean)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	8.376	6.358

"Following multiple dosing to steady state of abiraterone 1000 mg once daily, the Cohort 2 abiraterone tmax,ss is presented for abiraterone monotherapy and for olaparib given in combination with abiraterone.~Only patients with data available for analysis at each time point are presented." (NCT01972217)
Timeframe: PK sampling for Cohort 2 Group 1 was between Days 3 and 7 for olaparib, and Days 4 and 8 for olaparib and abiraterone. PK sampling for Cohort 2 Group 2 was between Days 5 and 7 for abiraterone, and Days 6 and 8 for olaparib and abiraterone.

Part A PK: Abiraterone Tmax,ss

Intervention	Hours (Median)
	Olaparib + abiraterone
Part A Cohort 2 Group 1: Olaparib, Olaparib + Abiraterone	3.000

Part A: Percentage of Patients Experiencing Adverse Events (AEs)

Intervention	Hours (Median)
	Abiraterone alone	Olaparib + abiraterone
Part A Cohort 2 Group 2: Abiraterone, Olaparib + Abiraterone	2.525	2.500

"The safety and tolerability of olaparib in combination with abiraterone was assessed during Part A of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events (CTCAE) v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related 'discont' = discontinuation." (NCT01972217)
Timeframe: Cohort 1 and 2: From baseline in Part A (Day 1 for each cohort) up to 30 days following last dose of study treatment.

Part B: Percentage of Patients Experiencing AEs

Intervention	Percentage of patients (Number)
	Any AE c-r to olaparib + abiraterone	Any AE c-r to olaparib only	Any AE c-r to abiraterone only	Any AE CTCAE Grade 3 or higher	Any AE CTCAE Grade 3 or higher c-r to olaparib	Any AE CTCAE Grade 3 or higher c-r to abiraterone	Any AE with outcome = death	Any serious AE (SAE)	Any SAE c-r to olaparib	Any SAE c-r to abiraterone	Any AE causing discont of olaparib	Any AE causing discont of olaparib c-r to olaparib	Any AE causing discont olaparib c-r to abiraterone
Part A Cohort 1: Olaparib 200 mg + Abiraterone	66.7	33.3	0	66.7	0	0	0	66.7	0	0	0	0	0
Part A Cohort 2: Olaparib 300 mg + Abiraterone	46.2	7.7	15.4	23.1	7.7	7.7	0	23.1	0	0	7.7	0	0

"The safety and tolerability of olaparib when given in combination with abiraterone was assessed during Part B of the study. The percentage of patients experiencing AEs, including information on seriousness, severity, study treatment relationship and those leading to discontinuation for all doses of olaparib and for abiraterone are presented.~Severity of AEs was assessed using the NCI Common Terminology CTCAE v4.0. AEs were assigned to a Grade from 1 through 5 as follows:~Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe or medically significant but not immediately life-threatening requiring hospitalisation; Grade 4: Life-threatening consequences; Grade 5: Death related to AE.~'c-r' = causally related. 'discont' = discontinuation. 'ola/pla' = olaparib/placebo." (NCT01972217)
Timeframe: From first dose of study treatment following randomisation in Part B up to 30 days following last dose of study treatment (up to approximately 3 years).

Part B: Percentage of Patients With PSA Responses

Intervention	Percentage of patients (Number)
	Any AE c-r to ola/pla + abiraterone	Any AE c-r to ola/pla only	Any AE c-r to abiraterone only	Any AE CTCAE Grade 3 or higher	Any AE CTCAE Grade 3 or higher c-r to ola/pla	Any AE CTCAE Grade 3 or higher c-r to abiraterone	Any AE with outcome = death	Any AE with outcome = death c-r to ola/pla	Any AE with outcome = death c-r to abiraterone	Any SAE	Any SAE c-r to ola/pla	Any SAE c-r to abiraterone	Any AE causing discont of ola/pla	Any AE causing discont of treatment c-r to ola/pla	Any AE causing discont treatment c-r abiraterone
Part B: Olaparib + Abiraterone	45.1	18.3	1.4	53.5	23.9	16.9	5.6	1.4	0	35.2	9.9	5.6	29.6	16.9	8.5
Part B: Placebo + Abiraterone	12.7	9.9	7.0	28.2	5.6	1.4	1.4	0	0	19.7	1.4	0	9.9	5.6	1.4

"The percentages of patients with single visit responses and with confirmed responses are presented to assess the anti-tumour activity of olaparib when given in addition to abiraterone, compared with placebo given in addition to abiraterone.~A single visit response was defined as any post-dose visit PSA level reduced by 50% or more compared with baseline.~A confirmed response was defined as a reduction in PSA level of 50% or more on 2 consecutive occasions at least 4 weeks apart compared with baseline.~Patients may have had more than 1 single visit response or confirmed response but were counted once." (NCT01972217)
Timeframe: From baseline, then every 4 weeks up to Week 24, and then every 12 weeks.

Overall Survival

Intervention	Percentage of patients (Number)
	Single visit response	Confirmed response
Part B: Olaparib + Abiraterone	50.7	47.9
Part B: Placebo + Abiraterone	47.9	42.3

Overall survival is defined as the time from randomization to date of death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to end of study (Month 60)

Radiographic Progression-free Survival (rPFS)

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	34.66
Placebo	30.29

The rPFS was defined as the time from randomization to the occurrence of one of the following: 1) a participant was considered to have progressed by bone scan if - a) the first bone scan with greater than or equal to (>=) 2 new lesions compared to baseline was observed in less than (<) 12 weeks from randomization and was confirmed by a second bone scan taken >=6 weeks later showing >=2 additional new lesions (a total of >=4 new lesions compared to baseline), b) the first bone scan with >=2 new lesions compared to baseline was observed in >=12 weeks from randomization and the new lesions were verified on the next bone scan >=6 weeks later (a total of >=2 new lesions compared to baseline); 2) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI); 3) death from any cause. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	NA
Placebo	8.28

The time interval from the date of randomization to the first date at which there was at least a 1 grade change (worsening) in the ECOG performance status grade. Participants who had no deterioration in ECOG performance status grade at the time of the analysis were censored at the last known date of no deterioration. ECOG is a 5-point scale, where 0=Fully active, 1=Ambulatory, carry out work of sedentary nature, 2=Ambulatory, capable of all self-care, 3=Capable of limited self-care, confined to bed or chair more than 50% of waking hours, 4=Completely disabled, no self-care, totally confined to bed or chair, 5=Dead. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18)

Time to Initiation of Cytotoxic Chemotherapy

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	12.29
Placebo	10.87

The time interval from the date of randomization to the date of initiation of cytotoxic chemotherapy for prostate cancer. Participants who had no cytotoxic chemotherapy administration at the time of analysis were censored at the last known date when no cytotoxic chemotherapy was administered. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to initiation of cytotoxic chemotherapy or cutoff date (Month 18)

Time to Opiate Use for Prostate Cancer Pain

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	25.17
Placebo	16.82

The time interval from the date of randomization to the date of opiate use for cancer pain. Participants who have no opiate use at the time of analysis were censored at the last known date of no opiate use for cancer pain. Participants with no assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to first opiate use or end of study (Month 60)

Time to Prostate-specific Antigen (PSA) Progression

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	33.38
Placebo	23.39

The time interval from the date of randomization to the date of PSA progression as defined in the protocol-specific prostate cancer Working Group 2 (PCWG2) criteria. A participant was considered to have a PSA progression if the PSA level had a 25 percent (%) or greater increase from nadir and an absolute increase of 2 nanogram/milliliter ((ng/mL) or more, which is confirmed by a second value obtained in 3 or more weeks. Participants who had no PSA progression at the time of the analysis were censored at the last known date of no PSA progression. Participants with no on-study PSA assessment or no baseline PSA assessment were censored at the date of randomization. (NCT00887198)
Timeframe: From randomization (Day 1) up to date of PSA progerssion or cutoff date (Month 18)

Number of Participants With Treatment Emergent Adverse Events

Intervention	Months (Median)
Abiraterone Acetate + Prednisone (AAP)	11.07
Placebo	5.55

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. (NCT00887198)
Timeframe: From first dose of study drug up to 30 days after the last dose of study drug

ACR 20 Response Rate at Visit 4

Intervention	Participants (Number)
	With Treatment-Emergent Adverse Events	With Treatment-Emergent Serious Adverse Events
Abiraterone Acetate + Prednisone (AAP)	541	208
Placebo	524	148
Placebo to Abiraterone Acetate	93	39

"Responders were defined as patients whose improvement from baseline to Visit 4 (Week 12) fulfilled all 3 of the following criteria:~> 20% reduction in the tender joint count (0-28)~> 20% reduction in the swollen joint count (0-28)~> 20% reduction in 3 out of the 5 following additional measures:~Patient's assessment of pain~Patient's global assessment of disease activity~Physician's global assessment of disease activity~Functional Disability Index of the Health Assessment Questionnaire~C-reactive protein or erythrocyte sedimentation rate" (NCT00650078)
Timeframe: Week 12

Relative Reduction of Morning Stiffness

Intervention	participants (Number)
NP01	108
Placebo	34

Data for the duration of morning stiffness were obtained from patient diaries. Duration of morning stiffness was the difference between the time of resolution of morning stiffness and the time of wake-up. Duration of morning stiffness is the average of the morning stiffness duration (minutes) over the last 7 days prior to visit day (including day of visit). If more than 4 assessments were missing, then the duration was set to missing. Baseline was the value recorded at Week -1 (Visit 0). (NCT00650078)
Timeframe: Week 12

Amount of Pain Medication - Day 1 to 48 Hours

Intervention	Relative Change from Baseline (%) (Median)
NP01	-55.22
Placebo	-34.62

Number of times the subject needed to use pain medication between day 1 and the 48 hour follow-up (NCT01671423)
Timeframe: Assessed once during the 48 hour follow-up

Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours

Intervention	medications taken (Median)
Prednisone	7
Placebo	2

The level of pain as measured by a Visual Analog Scale(VAS) measured once at day 1 and once during the 48th hour follow-up visit. Minimum value 0, maximum value 100mm, higher scores corresponds to more pain/worse outcomes. (NCT01671423)
Timeframe: Assessed once at day 1 and then once during the 48 hour follow-up

Toxicity and Tolerability of Experimental Arm

Intervention	score on a scale (Mean)
	VAS at Day 1	VAS at 48 hrs
Placebo	56.45	25.91
Prednisone	79.64	39.71

Descriptive analysis of observed toxicity and patient reports of tolerating experimental treatment (NCT03261336)
Timeframe: 2 years

Article	Year
Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. Oxidative medicine and cellular longevity, 2022, Volume: 2022 Topics: Anticonvulsants; Etanercept; Humans; Lamotrigine; Levetiracetam; Network Meta-Analysis; Pain; Pamidr	2022
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherap	2013
Eosinophilic cystitis: three cases, and a review over 10 years. BMJ case reports, 2014, Oct-13, Volume: 2014 Topics: Adolescent; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Cystitis; Diagnosis, Differential; Eo	2014
Idiopathic orbital inflammatory syndrome without pain: a case report. Optometry (St. Louis, Mo.), 2010, Volume: 81, Issue:3 Topics: Aged; Conjunctival Diseases; Dacryocystitis; Diagnosis, Differential; Edema; Humans; Inflammation; M	2010
[Retroperitoneal fibrosis, an unrecognized inflammatory disease. Clinical observations and review of the literature]. Nephrologie, 2003, Volume: 24, Issue:4 Topics: Aged; Anemia; Aortic Aneurysm; Female; Humans; Inflammation; Male; Middle Aged; Pain; Prednisone; Pr	2003
Chronic recurrent multifocal osteomyelitis of the spine and mandible: case report and review of the literature. Pediatrics, 2004, Volume: 113, Issue:4 Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Child, Preschool; Chron	2004
Analgesic efficacy of dextropropoxyphene and dextropropoxyphene-containing combinations: a review. Human toxicology, 1984, Volume: 3 Suppl Topics: Acetaminophen; Aminoacridines; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chlorambucil	1984
Therapeutic approaches to the management of herpes zoster. Advances in experimental medicine and biology, 1999, Volume: 458 Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Herpes Zoster; Humans; Pain; Prednisone; Pr	1999
Treatment of hormone refractory prostate cancer. Seminars in urologic oncology, 2001, Volume: 19, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est	2001
[Adult Still's disease: study of a series of 11 cases]. Journal des maladies vasculaires, 2002, Volume: 27, Issue:1 Topics: Adult; Anemia; Diagnosis, Differential; Exanthema; Female; Ferritins; Fever; Humans; Incidence; Infe	2002
[Primary hyperparathyroidism. An analysis of 152 patients with special references to acute life threatening complications (acute hyperparathyroidism)]. Schweizerische medizinische Wochenschrift, 1976, Volume: 106 Suppl 3 Topics: Acute Disease; Adenoma; Adolescent; Adult; Aged; Alkaline Phosphatase; Bone and Bones; Calcium; Diab	1976
[Polymyositis]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1976, Volume: 82 Pt 1 Topics: Antineoplastic Agents; Child; Dermatomyositis; Enzymes; Humans; Immunosuppression Therapy; Methotrex	1976
[Multiple myeloma. Biological, prognostic, and therapeutic aspects]. Sangre, 1990, Volume: 35, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Transplantation; Comb	1990
[Algodystrophic syndromes]. Wiadomosci lekarskie (Warsaw, Poland : 1960), 1974, Jul-15, Volume: 27, Issue:14 Topics: Adult; Age Factors; Alcoholism; Diabetes Complications; Female; Humans; Hyperthyroidism; Male; Pain;	1974

Article	Year
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:10 Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Doceta	2022
Three-dimensional facial swelling evaluation of pre-operative single-dose of prednisone in third molar surgery: a split-mouth randomized controlled trial. BMC oral health, 2023, 08-31, Volume: 23, Issue:1 Topics: Adult; Disease Progression; Female; Humans; Male; Molar, Third; Mouth; Pain; Prednisone; Retrospecti	2023
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. European urology, 2018, Volume: 74, Issue:1 Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Huma	2018
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Abiraterone Acetate; Activities of Daily Living; Androstadienes; Antineoplastic Combined Chemotherap	2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. Journal of the National Cancer Institute, 2013, Nov-20, Volume: 105, Issue:22 Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomar	2013
Improvement Thresholds for Morning Stiffness Duration in Patients Receiving Delayed- Versus Immediate-Release Prednisone for Rheumatoid Arthritis. Bulletin of the Hospital for Joint Disease (2013), 2015, Volume: 73, Issue:3 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Circadian Rhythm; Delayed-Action Preparati	2015
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU international, 2008, Aug-05, Volume: 102, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male;	2008
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009, Volume: 18, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone;	2009
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic A	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie	2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie	2010
Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Annals of the rheumatic diseases, 2013, Volume: 72, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoi	2013
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Com	2012
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-01, Volume: 21, Issue:17 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clodronic Acid; Disease Progre	2003
Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leukemia & lymphoma, 2003, Volume: 44, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Combined Modalit	2003
[Treatment of functional signs of acute maxillary rhinosinusitis in adults. Efficacy and tolerance of administration of oral prednisone for 3 days]. Presse medicale (Paris, France : 1983), 2004, Mar-13, Volume: 33, Issue:5 Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-In	2004
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial. Neurology, 2004, Aug-10, Volume: 63, Issue:3 Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ	2004
Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi. Haematologica, 2004, Volume: 89, Issue:8 Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Appetite; Bleomycin; Cyclophos	2004
Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clinical rheumatology, 2005, Volume: 24, Issue:2 Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid;	2005
Adjuvant prednisone therapy in pharyngitis: a randomised controlled trial from general practice. The British journal of general practice : the journal of the Royal College of General Practitioners, 2005, Volume: 55, Issue:512 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Chemotherapy, Adjuvant; Dose-Response Relationshi	2005
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel;	2006
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel;	2006
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel;	2006
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-20, Volume: 24, Issue:18 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel;	2006
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol	2007
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, May-01, Volume: 14, Issue:9 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone;	2008
Analgesic efficacy of dextropropoxyphene and dextropropoxyphene-containing combinations: a review. Human toxicology, 1984, Volume: 3 Suppl Topics: Acetaminophen; Aminoacridines; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Chlorambucil	1984
Low dose prednisone therapy in rheumatoid arthritis: a double blind study. The Journal of rheumatology, 1983, Volume: 10, Issue:5 Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Femal	1983
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco	1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco	1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco	1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6 Topics: Adenocarcinoma; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protoco	1996
Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Annals of internal medicine, 1996, Sep-01, Volume: 125, Issue:5 Topics: Acyclovir; Aged; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Glucocorticoi	1996
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. British journal of haematology, 1996, Volume: 94, Issue:2 Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Feeding a	1996
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group. British journal of haematology, 1997, Volume: 97, Issue:1 Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Forecasti	1997
Herpes zoster: risk categories for persistent pain. The Journal of infectious diseases, 1999, Volume: 179, Issue:1 Topics: Activities of Daily Living; Acyclovir; Aged; Anti-Inflammatory Agents; Antiviral Agents; Female; Her	1999
Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs. Rheumatology (Oxford, England), 2002, Volume: 41, Issue:3 Topics: Aged; Antibodies, Monoclonal; Antirheumatic Agents; Azathioprine; Drug Resistance; Drug Therapy, Com	2002
Evaluation of analgesic action and efficacy of antirheumatic drugs. Study of 10 drugs in 684 patients with rheumatoid arthritis. The Journal of rheumatology, 1976, Volume: 3, Issue:3 Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Clinical Tri	1976
[Comparative evaluation of the therapeutic efficiency of flurbiprofene in rheumatoid polyarthritis]. Revue du rhumatisme et des maladies osteo-articulaires, 1975, Volume: 42, Issue:6 Topics: Acetaminophen; Arthritis, Rheumatoid; Aspirin; Biphenyl Compounds; Chemical Phenomena; Chemistry; Cl	1975
Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. International journal of clinical pharmacology research, 1992, Volume: 12, Issue:1 Topics: Adult; Aged; Analysis of Variance; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male;	1992
Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis and rheumatism, 1992, Volume: 35, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Biopsy; Drug Administration Schedule; Humans; Liver; Liver Cirrhosis; M	1992
Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. British medical journal, 1973, Jun-23, Volume: 2, Issue:5868 Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Methods;	1973
Treatment of pain in hemophilia. Effect of drugs on bleeding time. American journal of diseases of children (1960), 1974, Volume: 127, Issue:3 Topics: Administration, Oral; Analgesics; Aspirin; Blood Coagulation; Blood Coagulation Tests; Blood Platele	1974
Proceedings: Technique for assessing the potential effectiveness of antirheumatic drugs. Annals of the rheumatic diseases, 1974, Volume: 33, Issue:1 Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Evaluation; Ethics, Medical; Humans;	1974
[Experience with paramethasone in sarcoidosis]. Medizinische Klinik, 1970, Sep-04, Volume: 65, Issue:36 Topics: Female; Humans; Lung Diseases; Male; Middle Aged; Pain; Paramethasone; Prednisone; Psychoses, Substa	1970

Article	Year
Orexin receptors in the CA1 region of hippocampus modulate the stress-induced antinociceptive responses in an animal model of persistent inflammatory pain. Peptides, 2022, Volume: 147 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoxazoles; CA1 Region, Hippocampal; Cycl	2022
Stridor Due to Cranial Nerve X Palsy Progressing to Polyneuropathy in a Teenager With COVID-19. Pediatrics, 2021, 12-01, Volume: 148, Issue:6 Topics: Acute Disease; Adolescent; Combined Modality Therapy; COVID-19; Deglutition Disorders; Diagnosis, Di	2021
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO open, 2022, Volume: 7, Issue:2 Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Pain; Predn	2022
Quality of life outcomes for patients with metastatic castration-resistant prostate cancer and pretreatment prognostic score. The Prostate, 2023, Volume: 83, Issue:7 Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; P	2023
Recurrent diabetic myonecrosis in an African American woman with long-standing uncontrolled type 2 diabetes: a case report. Journal of medical case reports, 2023, Jun-13, Volume: 17, Issue:1 Topics: Biopsy; Black or African American; Diabetes Mellitus, Type 2; Female; Humans; Infarction; Middle Age	2023
T-Cell Lymphoblastic Lymphoma Presenting as Acute Clavicular Pain. South Dakota medicine : the journal of the South Dakota State Medical Association, 2019, Volume: 72, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Daunorubicin; Humans; Pain; Precursor Cell Ly	2019
Acute Kidney Injury With Massively Enlarged Noncystic Kidneys. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 75, Issue:5 Topics: Acute Kidney Injury; Adolescent; Biopsy; Diagnosis, Differential; Female; Glomerular Filtration Rate	2020
Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences. Pediatric rheumatology online journal, 2021, Feb-17, Volume: 19, Issue:1 Topics: Adolescent; Analgesics; Antirheumatic Agents; Child; Dermatomyositis; Female; Fractures, Bone; Fract	2021
Atypical Sympathetic Ophthalmia Presenting with Ocular Pain Associated with Posterior Scleral Involvement. Ocular immunology and inflammation, 2022, Volume: 30, Issue:6 Topics: Adult; Choroid; Female; Fluorescein Angiography; Humans; Ophthalmia, Sympathetic; Pain; Prednisone	2022
Isolated Polyarteritis Nodosa Presenting as Bilateral Testicular Swelling. The American journal of medicine, 2018, Volume: 131, Issue:2 Topics: Cyclophosphamide; Debridement; Edema; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Metho	2018
Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step. European urology, 2018, Volume: 74, Issue:1 Topics: Abiraterone Acetate; Humans; Male; Neoplasm Grading; Pain; Prednisone; Prostate-Specific Antigen; Pr	2018
An Unusual Cause of Leg Pain. The New England journal of medicine, 2017, Nov-16, Volume: 377, Issue:20 Topics: Aged; Biopsy; Carotid Arteries; Coronary Angiography; Coronary Artery Bypass; Coronary Stenosis; Dru	2017
Extremely Painful Multifocal Acquired Predominant Axonal Sensorimotor Neuropathy of the Upper Limb. Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2018, Volume: 37, Issue:6 Topics: Aged; Autoimmune Diseases of the Nervous System; Brachial Plexus Neuritis; Diagnosis, Differential;	2018
Woman With Hand Pain and Swelling. Annals of emergency medicine, 2018, Volume: 71, Issue:6 Topics: Adult; Anti-Inflammatory Agents; Calcinosis; Edema; Emergency Service, Hospital; Female; Hand; Human	2018
Systemic lupus erythematosus-associated neutrophilic dermatosis manifesting as an acneiform eruption and foot pain. Clinical and experimental dermatology, 2019, Volume: 44, Issue:7 Topics: Acneiform Eruptions; Antirheumatic Agents; Female; Foot; Glucocorticoids; Humans; Hydroxychloroquine	2019
What Is the Optimal Dose of Predniso(lo)ne for Induction of Remission in Patients With Autoimmune Hepatitis? Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:8 Topics: Acetaminophen; Hepatitis, Autoimmune; Humans; Pain; Prednisolone; Prednisone; Remission Induction	2020
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO). BMC cancer, 2019, Aug-05, Volume: 19, Issue:1 Topics: Abiraterone Acetate; Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Anemia; Antineoplastic Ag	2019
A rare cause of odynophagia and dysphagia: oesophageal lichen planus. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2013, Volume: 14, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Deglutition Disorders; Esophagus; Female; Humans; Lichen Planus; Mu	2013
Chronic inflammatory demyelinating polyneuropathy associated with neurosyphilis. The American journal of the medical sciences, 2015, Volume: 349, Issue:1 Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Biopsy; Cognitive Dysfunction; Electromyography; Ex	2015
Painful acute radiation thyroiditis induced by 131I treatment of Graves' disease. BMJ case reports, 2015, Jan-09, Volume: 2015 Topics: Acetaminophen; Adult; Analgesics, Opioid; Anti-Inflammatory Agents; Drug Combinations; Female; Grave	2015
Polymyalgia rheumatica: inflammation suppression with low dose of methylprednisolone or modified-release prednisone. European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:5 Topics: Aged; Biomarkers; Cytokines; Female; Glucocorticoids; Humans; Inflammation; Interleukin-6; Male; Met	2015
Necrotizing crescentic glomerulonephritis related to sarcoidosis: a case report. Journal of medical case reports, 2015, Dec-14, Volume: 9 Topics: Adult; Azathioprine; Black or African American; Creatinine; Female; Foot Diseases; Glomerulonephriti	2015
[Neuralgic amyotrophy--a case report]. Przeglad lekarski, 2015, Volume: 72, Issue:7 Topics: Axons; Brachial Plexus Neuritis; Electromyography; Female; Humans; Middle Aged; Muscle, Skeletal; Pa	2015
Outcome of a glucocorticoid discontinuation regimen in patients with inactive systemic sclerosis. Clinical rheumatology, 2016, Volume: 35, Issue:8 Topics: Adult; Aged; Disability Evaluation; Fatigue; Female; Glucocorticoids; Health Status Indicators; Huma	2016
Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. Drug design, development and therapy, 2016, Volume: 10 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Cohort Studies; Female; Humans; Male; Midd	2016
An adolescent with fever, weakness, and pain. Clinical pediatrics, 2009, Volume: 48, Issue:7 Topics: Adolescent; Anti-Bacterial Agents; Diagnosis, Differential; Fever; Glucocorticoids; Humans; Male; Mu	2009
Vacuum-assisted biopsy and steroid therapy for granulomatous lobular mastitis: report of three cases. Surgery today, 2009, Volume: 39, Issue:8 Topics: Abscess; Adult; Biopsy; Combined Modality Therapy; Drainage; Female; Glucocorticoids; Granuloma; Hum	2009
Terbinafine-induced acute generalized exanthematous pustulosis (AGEP) responsive to high dose intravenous corticosteroid. Dermatology online journal, 2009, Sep-15, Volume: 15, Issue:9 Topics: Acute Generalized Exanthematous Pustulosis; Anti-Inflammatory Agents; Antifungal Agents; Clobetasol;	2009
Posttraumatic psoriatic osteitis of the frontal bone successfully treated with etanercept. Report of a case. Joint bone spine, 2010, Volume: 77, Issue:1 Topics: Acetaminophen; Anti-Inflammatory Agents; Child; Craniocerebral Trauma; Drug Therapy, Combination; Et	2010
Syringomyelia in the Cavalier King Charles spaniel (CKCS) dog. The Canadian veterinary journal = La revue veterinaire canadienne, 2010, Volume: 51, Issue:1 Topics: Amines; Analgesics; Animals; Anti-Inflammatory Agents; Arnold-Chiari Malformation; Breeding; Cyclohe	2010
Perplexing pyretic polyarthritis. Journal of the Mississippi State Medical Association, 2010, Volume: 51, Issue:4 Topics: Aged; Anti-Inflammatory Agents; Arthritis; Colchicine; Diagnosis, Differential; Fever; Gout; Gout Su	2010
Testicular pain followed by microscopic hematuria, a renal mass, palpable purpura, polyarthritis, and hematochezia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2010, Volume: 16, Issue:8 Topics: Adrenal Cortex Hormones; Adult; Arthritis; Carcinoma, Renal Cell; Gastrointestinal Hemorrhage; Hemat	2010
Painful genital ulcers in a 10-year old girl. Child abuse & neglect, 2011, Volume: 35, Issue:3 Topics: Anti-Inflammatory Agents; Child; Child Abuse, Sexual; Female; Humans; Pain; Prednisone; Pyoderma Gan	2011
Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bi	2003
Sarcomatoid variant of B-cell lymphoma of the uterine cervix. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2003, Volume: 22, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Female	2003
An unusual presentation of herpes zoster ophthalmicus: orbital myositis preceding vesicular eruption. American journal of ophthalmology, 2003, Volume: 136, Issue:3 Topics: Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Diplopia; Drug Therapy, Combination; Female;	2003
Lightning pain of tabes dorsalis treated with meticorten. New York state journal of medicine, 1958, Jul-01, Volume: 58, Issue:13 Topics: Humans; Lightning; Pain; Prednisone; Tabes Dorsalis	1958
[THE ALGOGENIC RECEPTIVITY OF MUSCLE IN VARIOUS PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS. III. ACTION OF PREDNISONE, ACETYLSALICYLIC ACID AND PHENYLBUTAZONE ON THE PERCEPTION OF MUSCULAR PAIN IN THE NORMAL SUBJECT AND IN THE RHEUMATIC SUBJECT]. Rassegna di neurologia vegetativa, 1963, Feb-28, Volume: 17 Topics: Arthritis; Arthritis, Rheumatoid; Aspirin; Hyperesthesia; Muscles; Myalgia; Pain; Perception; Pharma	1963
ABDOMINAL PAIN IN SCHOENLEIN-HENOCH SYNDROME. ITS CORRELATION WITH SMALL BOWEL BARIUM ROENTGEN STUDY. American journal of diseases of children (1960), 1964, Volume: 108 Topics: Abdomen; Abdominal Pain; Barium; Child; Drug Therapy; Gastrointestinal Hemorrhage; Humans; IgA Vascu	1964
CHEST PAIN, DYSPNEA, AND COR PULMONALE. JAMA, 1965, Feb-15, Volume: 191 Topics: Angiography; Chest Pain; Digoxin; Drug Therapy; Dyspnea; Humans; Pain; Pathology; Prednisone; Pulmon	1965
ACUTE CERVICAL PAIN ASSOCIATED WITH RETROPHARYNGEAL CALCIUM DEPOSIT. A CASE REPORT. The Journal of bone and joint surgery. American volume, 1964, Volume: 46 Topics: Axis, Cervical Vertebra; Calcinosis; Calcium; Cervical Atlas; Drug Therapy; Humans; Meperidine; Neck	1964
[Emergency treatment of post-traumatic orbital emphysema: a case report]. Journal francais d'ophtalmologie, 2003, Volume: 26, Issue:9 Topics: Anti-Inflammatory Agents; Cephalothin; Combined Modality Therapy; Diplopia; Drainage; Drug Therapy,	2003
Spinal cord schistosomiasis: a prospective study of 63 cases emphasizing clinical and therapeutic aspects. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2004, Volume: 11, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antiplatyhelmintic Agents; Biopsy; Child; Child,	2004
Lesser trochanteric bursitis: a rare cause of anterior hip pain. Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, 2004, Volume: 14, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Bursitis; Female; Femur; Follow-Up Studies; Hip Joint; Humans; Pain	2004
Combined central retinal artery and vein occlusion from orbital inflammatory pseudotumour. Clinical & experimental ophthalmology, 2004, Volume: 32, Issue:4 Topics: Adult; Exophthalmos; Fluorescein Angiography; Glucocorticoids; Humans; Magnetic Resonance Imaging; M	2004
Painful neuropathy vasculitis in 2 patients with long-standing human immunodeficiency virus-1 infection. Scandinavian journal of infectious diseases, 2004, Volume: 36, Issue:5 Topics: Adult; Antiretroviral Therapy, Highly Active; Follow-Up Studies; HIV Infections; HIV-1; Humans; Long	2004
[Contribution of corticosteroid to the treatment of pain in the acute phase of Guillain-Barré syndrome]. Revue neurologique, 2004, Volume: 160, Issue:8-9 Topics: Glucocorticoids; Guillain-Barre Syndrome; Humans; Male; Methylprednisolone; Middle Aged; Pain; Predn	2004
Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. International journal of radiation oncology, biology, physics, 2004, Dec-01, Volume: 60, Issue:5 Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Cost-Benefit Analysis; Humans; Male; Markov Chain	2004
Clinical problem-solving. Clear as mud. The New England journal of medicine, 2005, May-05, Volume: 352, Issue:18 Topics: Adolescent; Anti-Bacterial Agents; Blood Chemical Analysis; Creatinine; Diagnosis, Differential; Glu	2005
Bilateral isolated phrenic neuropathy causing painless bilateral diaphragmatic paralysis. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Adult; Aged; Anti-Inflammatory Agents; Autoimmune Diseases of the Nervous System; Brachial Plexus Ne	2005
Painful purpuric plaques on edematous hands. Archives of dermatology, 2005, Volume: 141, Issue:11 Topics: Administration, Oral; Aged; Carcinosarcoma; Edema; Hand; Humans; Male; Neoplasm Metastasis; Pain; Pa	2005
Retrospective review of the clinical manifestations and outcomes in Puerto Ricans with idiopathic inflammatory myopathies. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2005, Volume: 11, Issue:3 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Arthritis, Rheumatoid; Biopsy;	2005
The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain : a journal of neurology, 2006, Volume: 129, Issue:Pt 2 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age of Onset; Aged; Brachial Plexus; Brachial Plexus Neu	2006
Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis and rheumatism, 2006, Aug-15, Volume: 55, Issue:4 Topics: Adult; Cognition; Depression; Ethnicity; Fatigue; Female; Humans; Lupus Erythematosus, Systemic; Mal	2006
[Fractures of vital teeth during chronic pain therapy with oxycodone]. Deutsche medizinische Wochenschrift (1946), 2006, Nov-17, Volume: 131, Issue:46 Topics: Aged; Analgesics, Opioid; Animals; Glucocorticoids; Humans; Male; Oxycodone; Pain; Prednisone; Tooth	2006
Gout, have we met before? No, not like this... Journal of general internal medicine, 2006, Volume: 21, Issue:12 Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Arthritis, Gouty; Arthritis, Infectious; Diagn	2006
Childhood steroid-responsive painful opthalmoplegia: clues to opthalmoplegic migraine. The Journal of pediatrics, 2006, Volume: 149, Issue:6 Topics: Child; Female; Glucocorticoids; Humans; Migraine Disorders; Ophthalmoplegia; Pain; Prednisone; Remis	2006
[Intravascular lymphoma causing acute abdomen]. Der Pathologe, 2007, Volume: 28, Issue:1 Topics: Abdomen, Acute; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyc	2007
Steroid treatment in children with sickle-cell disease. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adolescent; Anemia, Sickle Cell; Arthritis; Autoimmune Diseases; Blood Transfusion; Child; Child, Pr	2007
Nudulo-cystic eruption with musculoskeletal pain. The Journal of family practice, 2007, Volume: 56, Issue:3 Topics: Acne Vulgaris; Adolescent; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio	2007
Eosinophilic fasciitis in a 57-year-old Japanese-American woman. Hawaii medical journal, 2007, Volume: 66, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis	2007
Responses of skin blood vessels to bradykinin, histamine and 5-hydroxytryptamine. The Journal of physiology, 1967, Volume: 193, Issue:2 Topics: Adult; Arteries; Blood Vessels; Bradykinin; Chlorpheniramine; Female; Histamine; Humans; Hydrocortis	1967
Painful ophthalmoplegia: report of a case. Acta ophthalmologica, 1967, Volume: 45, Issue:3 Topics: Adult; Exophthalmos; Humans; Male; Ophthalmoplegia; Pain; Papilledema; Prednisone	1967
Nine years of diarrhea and abdominal pain. Hospital practice (Office ed.), 1983, Volume: 18, Issue:5 Topics: Aged; Crohn Disease; Diarrhea; Duodenal Diseases; Female; Humans; Joint Diseases; Pain; Prednisone;	1983
Bone lesions in hairy cell leukemia. A case report and response of bone pains to steroids. Cancer, 1984, Jun-01, Volume: 53, Issue:11 Topics: Biopsy; Bone Neoplasms; Female; Humans; Leukemia, Hairy Cell; Middle Aged; Pain; Palliative Care; Pr	1984
Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Annals of neurology, 1984, Volume: 15, Issue:5 Topics: Aged; Blood Sedimentation; Cyclophosphamide; Female; Humans; Lumbosacral Plexus; Male; Middle Aged;	1984
Acne fulminans with prolonged polyarthralgia. International journal of dermatology, 1980, Volume: 19, Issue:10 Topics: Acne Vulgaris; Adult; HLA Antigens; Humans; Indomethacin; Joint Diseases; Male; Pain; Prednisone	1980
[Painful Tolosa-Hunt ophthalmoplegia]. Nederlands tijdschrift voor geneeskunde, 1984, Jun-23, Volume: 128, Issue:25 Topics: Adolescent; Adult; Female; Humans; Male; Middle Aged; Ophthalmoplegia; Orbit; Pain; Phlebography; Pr	1984
Respiratory tract symptoms as a clue to giant cell arteritis. Annals of internal medicine, 1984, Volume: 101, Issue:5 Topics: Aged; Cough; Female; Giant Cell Arteritis; Glossalgia; Hoarseness; Humans; Male; Middle Aged; Neck;	1984
Primary Hodgkin's disease of the lung. Case report and review of the literature. Blut, 1983, Volume: 47, Issue:4 Topics: Adult; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Hodgkin Disease; Humans; Lu	1983
Jaw claudication. Its value as a diagnostic clue. Postgraduate medicine, 1983, Volume: 73, Issue:2 Topics: Aged; Arthritis, Rheumatoid; Diagnosis, Differential; Female; Giant Cell Arteritis; Humans; Jaw Dise	1983
Unusual course of painful ophthalmoplegia. Report of a case. Acta ophthalmologica, 1980, Volume: 58, Issue:5 Topics: Abducens Nerve; Carotid Arteries; Cavernous Sinus; Cerebral Angiography; Humans; Male; Middle Aged;	1980
Bites and stings of uncommon arthropods. 1. Spiders. Postgraduate medicine, 1981, Volume: 70, Issue:2 Topics: Adult; Antivenins; Calcium Gluconate; Child; Dexamethasone; Female; Humans; Infant; Male; Muscle Rig	1981
Primary cutaneous histoplasmosis: a new presentation. Cutis, 1980, Volume: 25, Issue:2 Topics: Asthma; Biopsy; Cellulitis; Histoplasmosis; Humans; Male; Middle Aged; Pain; Prednisone; Skin Ulcer	1980
[Palliative treatment--prednisone for symptoms]. Sygeplejersken, 1994, Apr-27, Volume: 94, Issue:17 Topics: Brain Neoplasms; Humans; Hypercalcemia; Hypersensitivity; Nausea; Neoplasms; Pain; Palliative Care;	1994
Steroid-responsive myalgia in a patient with Becker muscular dystrophy. Journal of the neurological sciences, 1993, Volume: 115, Issue:2 Topics: Adult; Antibodies, Monoclonal; Histocytochemistry; Humans; Immunohistochemistry; Male; Muscles; Musc	1993
Protracted febrile myalgia in patients with familial Mediterranean fever. The Journal of rheumatology, 1994, Volume: 21, Issue:9 Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Colchicine; Dru	1994
Upper limb pain in chronic demyelinating polyneuropathy: electrophysiological correlates. Acta neurologica Scandinavica, 1994, Volume: 90, Issue:4 Topics: Arm; Demyelinating Diseases; Electric Stimulation; Female; Humans; Leg; Male; Middle Aged; Neurologi	1994
Bone marrow necrosis following ALL-trans retinoic acid therapy for acute promyelocytic leukaemia. Leukemia & lymphoma, 1994, Volume: 13, Issue:3-4 Topics: Bone Marrow; Female; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocyte Count; L	1994
Shoulder and back pain with morning stiffness in an elderly woman. Hospital practice (Office ed.), 1994, Aug-15, Volume: 29, Issue:8 Topics: Aged; Back Pain; Female; Humans; Pain; Polymyalgia Rheumatica; Prednisone; Shoulder	1994
[Churg-Strauss syndrome]. Deutsche medizinische Wochenschrift (1946), 1994, Apr-22, Volume: 119, Issue:16 Topics: Adult; Asthma; Back Pain; Blood Sedimentation; Bone Marrow; Churg-Strauss Syndrome; Dyspnea; Female;	1994
Unstable angina in a man with joint pain. Hospital practice (Office ed.), 1993, Jan-15, Volume: 28, Issue:1 Topics: Angina, Unstable; Arthritis, Rheumatoid; Coronary Disease; Diagnosis, Differential; Edema; Humans; M	1993
Giant cell arteritis of the breast. The Australian and New Zealand journal of surgery, 1996, Volume: 66, Issue:4 Topics: Aged; Anti-Inflammatory Agents; Biopsy; Breast Diseases; Diagnosis, Differential; Female; Giant Cell	1996
MMC in ONS decompression. Ophthalmology, 1996, Volume: 103, Issue:6 Topics: Adolescent; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Humans; Male; Mitomycin; Myelin S	1996
Pyomyositis during induction chemotherapy for acute lymphocytic leukemia. Journal of pediatric hematology/oncology, 1996, Volume: 18, Issue:3 Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; Child;	1996
The sympathetic skin response in the shoulder-hand syndrome complicating tetraplegia. Paraplegia, 1995, Volume: 33, Issue:10 Topics: Adolescent; Adult; Aged; Electrophysiology; Female; Humans; Male; Middle Aged; Pain; Prednisone; Qua	1995
Acyclovir or prednisone for treating herpes zoster. The Journal of family practice, 1996, Volume: 43, Issue:6 Topics: Acyclovir; Aged; Anti-Inflammatory Agents; Antiviral Agents; Drug Therapy, Combination; Evaluation S	1996
Effective treatment of painful bone crises in type I gaucher's disease with high dose prednisolone. Archives of disease in childhood, 1996, Volume: 75, Issue:3 Topics: Adolescent; Adult; Anti-Inflammatory Agents; Bone Diseases; Child; Drug Therapy, Combination; Gauche	1996
Case records of the Department of Medicine University of Mississippi Medical Center. Leukocytoclastic vasculitis, probable polyarteritis nodosa, clinically indolent lymphoma, but never firmly established. Journal of the Mississippi State Medical Association, 1997, Volume: 38, Issue:9 Topics: Aged; Biopsy; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, C	1997
Pain in Tolosa-Hunt syndrome. Journal of pain and symptom management, 1998, Volume: 16, Issue:3 Topics: Aged; Anti-Inflammatory Agents; Female; Humans; Magnetic Resonance Imaging; Orbital Pseudotumor; Pai	1998
Depression and the long-term risk of pain, fatigue, and disability in patients with rheumatoid arthritis. Arthritis and rheumatism, 1998, Volume: 41, Issue:10 Topics: Arthritis, Rheumatoid; Depression; Disability Evaluation; Fatigue; Humans; Methotrexate; Pain; Predn	1998
Painful Horner syndrome due to arteritis of the internal carotid artery. Neurology, 1998, Volume: 51, Issue:5 Topics: Adult; Arteritis; Blepharoptosis; Carotid Arteries; Carotid Artery Diseases; Horner Syndrome; Humans	1998
Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecologic oncology, 1999, Volume: 72, Issue:1 Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Femal	1999
Magnetic resonance imaging of acquired Brown syndrome in a patient with psoriasis. American journal of ophthalmology, 1999, Volume: 127, Issue:2 Topics: Adult; Arthritis, Psoriatic; Diplopia; Eyelid Diseases; Female; Humans; Magnetic Resonance Imaging;	1999
Commentary: low-dose high-frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crises in patients with severe juvenile onset type I Gaucher disease. Blood cells, molecules & diseases, 1998, Volume: 24, Issue:3 Topics: Adolescent; Adult; Age Factors; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ste	1998
From twisted ankles. Medicine and health, Rhode Island, 1999, Volume: 82, Issue:6 Topics: Ankle Injuries; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Cast	1999
Painful tonic/dystonic spasms in Sjogren's syndrome. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antinuclear; Arm; Dystonic Disorders; Epilepsy, General	1999
Renal cholesterol microembolism: is steroid therapy effective? Nephron, 2000, Volume: 86, Issue:2 Topics: Acute Kidney Injury; Anticoagulants; Coronary Thrombosis; Cortisone; Cyanosis; Embolism, Cholesterol	2000
Severe and prolonged febrile myalgia in familial Mediterranean fever. Scandinavian journal of rheumatology, 2000, Volume: 29, Issue:6 Topics: Adolescent; Adult; Chronic Disease; Familial Mediterranean Fever; Female; Fever; Glucocorticoids; Hu	2000
Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. British journal of haematology, 2001, Volume: 114, Issue:1 Topics: Adult; Aged; Combined Modality Therapy; Cyclosporine; Drug Therapy, Combination; Female; Headache; H	2001
58-year-old man with fatigue and flank pain. Mayo Clinic proceedings, 2002, Volume: 77, Issue:2 Topics: Anti-Inflammatory Agents; Biopsy, Needle; Diagnosis, Differential; Fatigue; Humans; Hypercalcemia; L	2002
The reflex sympathetic dystrophy syndrome. I. Clinical and histologic studies: evidence for bilaterality, response to corticosteroids and articular involvement. The American journal of medicine, 1976, Volume: 60, Issue:3 Topics: Adult; Aged; Female; Humans; Joint Diseases; Middle Aged; Pain; Prednisone; Reflex Sympathetic Dystr	1976
[The Tolosa-Hunt syndrome (author's transl)]. Fortschritte der Neurologie, Psychiatrie, und ihrer Grenzgebiete, 1977, Volume: 45, Issue:8 Topics: Adolescent; Humans; Male; Middle Aged; Ophthalmoplegia; Pain; Prednisone; Prognosis; Syndrome; Time	1977
Tolosa-Hunt syndrome with sellar erosion. Annals of neurology, 1979, Volume: 6, Issue:2 Topics: Cavernous Sinus; Cerebral Angiography; Humans; Male; Middle Aged; Ophthalmoplegia; Pain; Prednisone;	1979
[Painful ophthalmoplegia. Tolosa-Hunt syndrome]. Ugeskrift for laeger, 1979, Nov-12, Volume: 141, Issue:46 Topics: Diagnosis, Differential; Humans; Ophthalmoplegia; Pain; Prednisone; Syndrome	1979
Painful ophthalmoplegia. Tropical and geographical medicine, 1977, Volume: 29, Issue:4 Topics: Adult; Female; Humans; Male; Middle Aged; Ophthalmoplegia; Pain; Prednisone; Syndrome; Zambia	1977
Painful ophthalmoplegia. The Tolusa-Hunt syndrome. Archives of otolaryngology (Chicago, Ill. : 1960), 1978, Volume: 104, Issue:6 Topics: Adult; Diagnosis, Differential; Humans; Male; Ophthalmoplegia; Pain; Prednisone; Syndrome	1978
[Prognosis and therapy of multiple myeloma]. Schweizerische medizinische Wochenschrift, 1978, Aug-12, Volume: 108, Issue:32 Topics: Blood Transfusion; Cyclophosphamide; Drug Therapy, Combination; Humans; Melphalan; Multiple Myeloma;	1978
A puzzling arthralgia. Hospital practice, 1978, Volume: 13, Issue:9 Topics: Biopsy; Female; Hepatitis; Humans; Joint Diseases; Liver; Liver Function Tests; Middle Aged; Pain; P	1978
Aseptic necrosis presenting as wrist pain in SLE. Arthritis and rheumatism, 1977, Volume: 20, Issue:3 Topics: Adolescent; Adult; Carpal Bones; Child; Diagnosis, Differential; Diagnostic Errors; Humans; Lupus Er	1977
Multiple myeloma: uncommon or uncommonly diagnosed? Postgraduate medicine, 1977, Volume: 61, Issue:5 Topics: Adult; Anemia; Blood Sedimentation; Bone Diseases; Female; Humans; Male; Melphalan; Middle Aged; Mul	1977
Hepatitis-associated lipid storage myopathy. Annals of internal medicine, 1977, Volume: 87, Issue:4 Topics: Adult; Biopsy; Female; Hepatitis B; Hepatitis B Surface Antigens; Humans; Lipid Metabolism, Inborn E	1977
Carotid system arteritis: an overlooked and misdiagnosed syndrome. Journal of the American Dental Association (1939), 1975, Volume: 91, Issue:3 Topics: Adult; Arteritis; Carotid Artery Diseases; Diagnosis, Differential; Face; Female; Head; Humans; Male	1975
Multiple myeloma: review of 869 cases. Mayo Clinic proceedings, 1975, Volume: 50, Issue:1 Topics: Adult; Aged; Bacterial Infections; Blood Cell Count; Blood Sedimentation; Bone and Bones; Calcium; C	1975
Arterial stationary wave phenomenon in Tolosa-Hunt syndrome. Neurology, 1975, Volume: 25, Issue:8 Topics: Adolescent; Arteritis; Carotid Artery, Internal; Cerebral Angiography; Cerebral Arteries; Female; Hu	1975
Diseases of the central nervous system. Relief of pain: headache, facial neuralgia, migraine, and phantom limb. British medical journal, 1975, Oct-11, Volume: 4, Issue:5988 Topics: Analgesics; Aspirin; Carbamazepine; Ergotamines; Facial Neuralgia; Giant Cell Arteritis; Headache; H	1975
[Administration of Hylase in Bechterew's disease]. Zeitschrift fur arztliche Fortbildung, 1975, Nov-01, Volume: 69, Issue:21 Topics: Adult; Carnitine; Drug Synergism; Humans; Hyaluronoglucosaminidase; Injections, Intravenous; Male; P	1975
Systemic necrotizing vasculitis in nine young beagles. Journal of the American Veterinary Medical Association, 1992, Nov-15, Volume: 201, Issue:10 Topics: Animals; Dog Diseases; Dogs; Female; Male; Pain; Polyarteritis Nodosa; Prednisone; Syndrome	1992
Steroid-responsive tubular aggregate myopathy. Muscle & nerve, 1991, Volume: 14, Issue:3 Topics: Biopsy; Humans; Male; Microtubules; Middle Aged; Muscle Cramp; Muscles; Pain; Prednisone; Sarcoplasm	1991
L-tryptophan induced eosinophilia-myalgia syndrome. The Journal of rheumatology, 1990, Volume: 17, Issue:11 Topics: Activities of Daily Living; Adult; Aged; Cell Count; Electrophysiology; Eosinophilia; Female; Humans	1990
Eosinophilia-myalgia syndrome associated with L-tryptophan use. The Journal of rheumatology, 1990, Volume: 17, Issue:11 Topics: Adult; Aged; Cell Count; Child; Eosinophilia; Eosinophils; Fatigue; Female; Humans; Male; Middle Age	1990
Adjunctive use of hydroxychloroquine in childhood dermatomyositis. The Journal of rheumatology, 1989, Volume: 16, Issue:12 Topics: Adolescent; Antineoplastic Agents; Child; Dermatomyositis; Drug Therapy, Combination; Female; Humans	1989
Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:5 Topics: Aged; Analgesics; Androgens; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prednisone; Prosp	1989
Optic neuropathy associated with chronic lymphomatous meningitis. Journal of clinical neuro-ophthalmology, 1988, Volume: 8, Issue:1 Topics: Biopsy; Bone Marrow; Chronic Disease; Eye; Humans; Lymphoma; Male; Meningitis; Middle Aged; Nasal Mu	1988
Recurrent abdominal pain and ascites in an adolescent. The Journal of pediatrics, 1988, Volume: 113, Issue:3 Topics: Abdomen; Adolescent; Ascites; Eosinophilia; Gastroenteritis; Humans; Male; Pain; Prednisone; Recurre	1988
M-2 protocol for melphalan-resistant and relapsing multiple myeloma. European journal of haematology, 1988, Volume: 40, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carmustine	1988
Odynophagia from aphthous ulcers of the pharynx and esophagus in the acquired immunodeficiency syndrome (AIDS). Annals of internal medicine, 1988, Aug-15, Volume: 109, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Deglutition Disorders; Esophageal Diseases; H	1988
Severe arthralgias after wide fluctuation in corticosteroid dosage. The Journal of rheumatology, 1986, Volume: 13, Issue:6 Topics: Adult; Female; Humans; Joint Diseases; Knee Joint; Male; Methylprednisolone; Middle Aged; Pain; Pred	1986
Steroid effects on the course of abdominal pain in children with Henoch-Schonlein purpura. Pediatrics, 1987, Volume: 79, Issue:6 Topics: Abdomen; Child; Humans; IgA Vasculitis; Pain; Prednisone; Retrospective Studies; Time Factors	1987
A new etiology for visual impairment and chronic headache. The Tolosa-Hunt syndrome may be only one manifestation of venous vasculitis. Cephalalgia : an international journal of headache, 1986, Volume: 6, Issue:1 Topics: Adolescent; Adult; Aged; Chronic Disease; Female; Headache; Humans; Male; Middle Aged; Ophthalmopleg	1986
Metoclopramide in vincristine-induced ileus. Cancer treatment reports, 1985, Volume: 69, Issue:11 Topics: Aged; Constipation; Gastrointestinal Motility; Humans; Intestinal Obstruction; Leukemia, Lymphoid; L	1985
Joint and muscle pains in an aging tennis player. Hospital practice (Office ed.), 1985, Nov-15, Volume: 20, Issue:11 Topics: Aging; Humans; Male; Middle Aged; Pain; Polymyalgia Rheumatica; Prednisone; Tennis	1985
Progressive diaphyseal dysplasia: evaluation of corticosteroid therapy. Pediatrics, 1985, Volume: 75, Issue:2 Topics: Adolescent; Adult; Camurati-Engelmann Syndrome; Child; Child, Preschool; Drug Administration Schedul	1985
Idiopathic eosinophilic myositis with preexisting fibromyalgia. The Journal of rheumatology, 1985, Volume: 12, Issue:1 Topics: Aged; Eosinophilia; Female; Humans; Joint Diseases; Muscular Diseases; Myositis; Pain; Prednisone	1985
Aseptic bone/bone marrow necrosis in leukaemia. Scandinavian journal of haematology, 1985, Volume: 35, Issue:3 Topics: Adolescent; Adult; Aged; Autopsy; Bone Diseases; Bone Marrow Diseases; Child; Child, Preschool; Fema	1985
Letter: Acute arthralgia following high-dose intravenous methylprednisolone therapy. Lancet (London, England), 1974, Jul-27, Volume: 2, Issue:7874 Topics: Acute Disease; Administration, Oral; Adult; Female; Graft Rejection; Humans; Injections, Intravenous	1974
Letter: Acute arthralgia after high-dose intravenous methylprednisolone. Lancet (London, England), 1974, Oct-26, Volume: 2, Issue:7887 Topics: Adult; Azathioprine; Drug Therapy, Combination; Female; Foreign-Body Reaction; Graft Rejection; Huma	1974
The drug therapy of ulcerative colitis and of Crohn's disease. Seminars in drug treatment, 1974,Spring, Volume: 3, Issue:4 Topics: Adrenocorticotropic Hormone; Atropine; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diarrhea; D	1974
Tegretol for pain in the Guillain-Barré syndrome. Lancet (London, England), 1970, Jan-10, Volume: 1, Issue:7637 Topics: Dibenzazepines; Female; Humans; Middle Aged; Pain; Polyradiculopathy; Prednisone	1970
Familial brachial neuropathy. Two case reports with discussion. Neurology, 1971, Volume: 21, Issue:9 Topics: Adolescent; Arm; Brachial Plexus; Follow-Up Studies; Humans; Male; Muscular Diseases; Neural Conduct	1971
[Peripheral neurologic manifestations of sarcoidosis]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1972, Nov-14, Volume: 48, Issue:46 Topics: Adrenal Cortex Hormones; Adult; Cauda Equina; Diagnosis, Differential; Fatigue; Humans; Leg; Male; N	1972
Periarteritis nodosa. A remission achieved with combined prednisone and azathioprine therapy. American journal of diseases of children (1960), 1971, Volume: 121, Issue:5 Topics: Abdomen, Acute; Adolescent; Azathioprine; Eosinophilia; Humans; Male; Neuritis; Pain; Polyarteritis	1971
Lymphosarcomatous arthropathy. Proceedings of the Royal Society of Medicine, 1974, Volume: 67, Issue:3 Topics: Arthritis; Biopsy; Cyclophosphamide; Female; Foot; Hand; Hematocrit; Humans; Lymphoma, Non-Hodgkin;	1974
Alternate-day corticosteroid therapy in juvenile chronic polyarthritis. The Journal of rheumatology, 1974, Volume: 1, Issue:2 Topics: Adolescent; Anemia; Arthritis, Juvenile; Body Height; Child; Child, Preschool; Chronic Disease; Drug	1974
[Experiences and results in the treatment of acute pancreatitis]. Zentralblatt fur Chirurgie, 1974, Sep-27, Volume: 99, Issue:39 Topics: Acute Disease; Aged; Analgesics; Anti-Bacterial Agents; Aprotinin; Blood Transfusion; Female; Humans	1974
Tolosa-Hunt syndrome and antinuclear factor. American journal of ophthalmology, 1974, Volume: 77, Issue:5 Topics: Antibodies, Antinuclear; Blood Sedimentation; Female; Fluorescent Antibody Technique; Humans; Middle	1974
The Tolosa-Hunt syndrome (painful ophthalmoplegia) in children. Developmental medicine and child neurology, 1973, Volume: 15, Issue:4 Topics: Blepharoptosis; Child; Child, Preschool; Female; Headache; Humans; Male; Ophthalmoplegia; Pain; Pred	1973
[Painful ophthalmoplegia. Report of 3 cases]. Arquivos de neuro-psiquiatria, 1974, Volume: 32, Issue:1 Topics: Adolescent; Adult; Carotid Arteries; Cerebral Angiography; Dexamethasone; Diagnosis, Differential; F	1974
Temporal arteritis. Postgraduate medicine, 1974, Volume: 56, Issue:3 Topics: Age Factors; Aged; Angiography; Biopsy; Blindness; Blood Proteins; Blood Sedimentation; Carotid Arte	1974
[On the treatment of inflammatory and degenerative diseases of the musculosketetal system with Vertebran]. Deutsches medizinisches Journal, 1968, Dec-05, Volume: 19, Issue:23 Topics: Atropine; Bone Diseases; Caffeine; Ergoloid Mesylates; Humans; Joint Diseases; Muscular Diseases; Pa	1968
Polyarthritis associated with Yersinia enterocolitica infection. Clinical features and laboratory findings in nine cases with severe joint symptoms. Annals of the rheumatic diseases, 1972, Volume: 31, Issue:1 Topics: Adult; Agglutination Tests; Anti-Bacterial Agents; Arthritis, Infectious; Complement Fixation Tests;	1972
[Painful ophthalmoplegia]. Bordeaux medical, 1972, Volume: 5, Issue:2 Topics: Adult; Aged; Cerebral Angiography; Cerebrovascular Disorders; Humans; Male; Migraine Disorders; Opht	1972
[Severe anguilluliatis revealed by corticosteroid therapy. Case]. La Nouvelle presse medicale, 1972, Jul-22, Volume: 1, Issue:29 Topics: Adult; Anorexia Nervosa; Biopsy; Blood Proteins; Diarrhea; Eosinophils; Female; Humans; Jejunum; Pai	1972
Recurrent right middle lobe syndrome in an asthmatic child. Case report and serial vectorcardiographic study. Clinical pediatrics, 1970, Volume: 9, Issue:11 Topics: Asthma; Child; Cough; Ephedrine; Female; Humans; Middle Lobe Syndrome; Pain; Phenobarbital; Predniso	1970
Corticosteroids in the treatment of Engelmann's disease: progressive diaphyseal dysplasia. Pediatrics, 1970, Volume: 46, Issue:4 Topics: Bone Resorption; Child, Preschool; Cortisone; Exostoses; Female; Femur; Fibula; Gait; Growth; Havers	1970
[Löfgren's syndrome (acute sarcoidosis)]. Medizinische Klinik, 1970, Sep-04, Volume: 65, Issue:36 Topics: Acute Disease; Adult; Biopsy; Cardiomyopathies; Erythema Nodosum; Female; Humans; Hypersensitivity;	1970
Pericarditis in chronic uremia and its sequels. Annals of internal medicine, 1971, Volume: 75, Issue:2 Topics: Adolescent; Adult; Age Factors; Arrhythmias, Cardiac; Autopsy; Blood Urea Nitrogen; Body Weight; Chr	1971
Report of a case of sphenoid fissure syndrome studied by orbital venography. American journal of ophthalmology, 1971, Volume: 72, Issue:3 Topics: Adolescent; Blepharoptosis; Cavernous Sinus; Centrifugation, Density Gradient; Constriction; Female;	1971
Myopathy of hypothyroidism. Annals of the rheumatic diseases, 1968, Volume: 27, Issue:6 Topics: Adult; Aged; Antibodies; Female; Humans; Hypothyroidism; Male; Middle Aged; Muscular Atrophy; Muscul	1968
[On the phlogogenic properties of lactic acid in animal experiments]. Arzneimittel-Forschung, 1968, Volume: 18, Issue:12 Topics: Animals; Capillary Permeability; Conjunctivitis; Edema; Exudates and Transudates; Guinea Pigs; Infla	1968
Giant cell arteritis with polymyalgia rheumatica, loss of vision, and abdominal symptoms occurring during a four year course. Arthritis and rheumatism, 1969, Volume: 12, Issue:2 Topics: Aged; Blindness; Blood Sedimentation; Diarrhea; Gastrointestinal Diseases; Giant Cell Arteritis; Hum	1969
Painful ophthalmoplegia. The Tolosa-Hunt syndrome. American journal of ophthalmology, 1966, Volume: 61, Issue:6 Topics: Cranial Nerves; Diagnosis, Differential; Diplopia; Eye Diseases; Female; Humans; Male; Middle Aged;	1966

prednisone and Ache

Research Excerpts

Research

Studies (212)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Part A: Number of Patients With Dose Limiting Toxicities (DLTs)

Part B: Median Best Percentage Change From Baseline in Circulating Tumour Cell (CTC) Level

Part B: Median Best Percentage Change From Baseline in Prostate Specific Antigen (PSA) Levels

Part B: Median Overall Survival (OS)

Part B: Median Radiological Progression-Free Survival (rPFS) Time

Part B: Median Time to Second Progression or Death (PFS2)

Part B: Percentage of Patients With at Least One Objective Response (Objective Response Rate [ORR])

Part B: Percentage of Patients With Progression Events or Death (rPFS)

Median Time to First Subsequent Therapy (TFST) and Median Time to Second Subsequent Therapy (TSST)

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Part A Pharmacokinetics (PK): Olaparib Maximum Plasma Concentration at Steady State (Cmax,ss)

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Part A PK Analysis: Olaparib Area Under the Plasma Concentration-Time Curve at Steady State (AUCss)

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Part A PK Analysis: Olaparib Minimum Plasma Concentration at Steady State (Cmin,ss)

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Part A PK Analysis: Olaparib Time to Reach Maximum Plasma Concentration at Steady State (Tmax,ss)

Part A PK: Abiraterone AUCss

Part A PK: Abiraterone AUCss

Part A PK: Abiraterone Cmax,ss

Part A PK: Abiraterone Cmax,ss

Part A PK: Abiraterone Cmin,ss

Part A PK: Abiraterone Cmin,ss

Part A PK: Abiraterone Tmax,ss

Part A PK: Abiraterone Tmax,ss

Part A: Percentage of Patients Experiencing Adverse Events (AEs)

Part B: Percentage of Patients Experiencing AEs

Part B: Percentage of Patients With PSA Responses

Overall Survival

Radiographic Progression-free Survival (rPFS)

Time to Deterioration in Eastern Cooperative Oncology Group (ECOG) Performance Score by >=1 Point

Time to Initiation of Cytotoxic Chemotherapy

Time to Opiate Use for Prostate Cancer Pain

Time to Prostate-specific Antigen (PSA) Progression

Number of Participants With Treatment Emergent Adverse Events

ACR 20 Response Rate at Visit 4

Relative Reduction of Morning Stiffness

Amount of Pain Medication - Day 1 to 48 Hours

Visual Analog Scale(VAS) for Pain - Day 1 to 48 Hours

Toxicity and Tolerability of Experimental Arm

Reviews

Trials

Other Studies